Agilent (A) 10-Q 30 May 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Apr. 30, 2019	May 23, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	AGILENT TECHNOLOGIES INC.
Entity Central Index Key	0001090872
Current Fiscal Year End Date	--10-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		315,993,352
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Document Type	10-Q
Amendment Flag	false
Entity Small Business	false
Entity Emerging Growth Company	false
Document Period End Date	Apr. 30, 2019

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Net revenue:
Net revenue	$ 1,238	$ 1,206	$ 2,522	$ 2,417
Costs and expenses:
Cost of revenue	569	563	1,146	1,104
Research and development	99	92	201	186
Selling, general and administrative	354	341	709	688
Total costs and expenses	1,022	996	2,056	1,978
Income from operations	216	210	466	439
Interest income	10	10	20	19
Interest expense	(17)	(19)	(35)	(39)
Other income (expense), net	9	26	15	41
Income before taxes	218	227	466	460
Provision (benefit) for income taxes	36	22	(220)	575
Net income (loss)	$ 182	$ 205	$ 686	$ (115)
Net income (loss) per share
Basic	$ 0.57	$ 0.64	$ 2.16	$ (0.36)
Diluted	$ 0.57	$ 0.63	$ 2.13	$ (0.36)
Weighted average shares used in computing net income (loss) per share:
Basic (in shares)	317	322	318	323
Diluted (in shares)	321	326	322	323
Product
Net revenue:
Net revenue	$ 921	$ 918	$ 1,901	$ 1,848
Costs and expenses:
Cost of revenue	400	403	814	789
Service, Other
Net revenue:
Net revenue	317	288	621	569
Costs and expenses:
Cost of revenue	$ 169	$ 160	$ 332	$ 315

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Net income (loss)	$ 182	$ 205	$ 686	$ (115)
Other comprehensive income (loss):
Unrealized gain (loss) on derivative instruments, net of tax expense (benefit) of $1, $1, $(1) and $2	3	4	(1)	(3)
Amounts reclassified into earnings related to derivative instruments, net of tax expense (benefit) of $0, $2, $(1) and $2	0	3	(4)	3
Foreign currency translation, net of tax expense (benefit) of $0, $0, $(9) and $0	(25)	(53)	13	26
Net defined benefit pension cost and post retirement plan costs:
Change in actuarial net loss, net of tax expense of $2, $3, $6 and $5	6	7	12	13
Change in net prior service benefit, net of tax benefit of $(1), $0, $(1) and $(1)	(1)	(2)	(3)	(3)
Other comprehensive income (loss)	(17)	(41)	17	36
Total comprehensive income (loss)	$ 165	$ 164	$ 703	$ (79)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Other comprehensive income (loss), tax, parenthetical disclosures
Unrealized gain (loss) on derivative instruments, tax	$ 1	$ 1	$ (1)	$ (2)
Amounts reclassified into earnings related to derivative instruments, tax	0	2	(1)	2
Foreign currency translation, tax	0	0	(9)	0
Net defined benefit pension cost and post retirement plan costs, tax
Change in actuarial net loss, tax	2	3	6	5
Change in net prior service benefit, tax	$ (1)	$ 0	$ (1)	$ (1)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Current assets:
Cash and cash equivalents	$ 2,155	$ 2,247
Accounts receivable, net	819	776
Inventory	657	638
Other current assets	181	187
Total current assets	3,812	3,848
Property, plant and equipment, net	827	822
Goodwill	3,112	2,973
Other intangible assets, net	538	491
Long-term investments	96	68
Other assets	637	339
Total assets	9,022	8,541
Current liabilities:
Accounts payable	314	340
Employee compensation and benefits	292	304
Deferred revenue	347	324
Other accrued liabilities	165	203
Total current liabilities	1,118	1,171
Long-term debt	1,798	1,799
Retirement and post-retirement benefits	229	239
Other long-term liabilities	752	761
Total liabilities	3,897	3,970
Commitments and Contingencies (Note 12)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0	0
Common stock; $0.01 par value; 2 billion shares authorized; 317 million shares at April 30, 2019 and 318 million shares at October 31, 2018, issued	(3)	(3)
Treasury stock at cost; 9 thousand shares at April 30, 2019 and zero shares at October 31, 2018	(1)	0
Additional paid-in-capital	5,343	5,308
Retained earnings (accumulated deficit)	178	(336)
Accumulated other comprehensive loss	(398)	(408)
Total stockholder's equity	5,125	4,567
Non-controlling interest	0	4
Total equity	5,125	4,571
Total liabilities and equity	$ 9,022	$ 8,541

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEET (Unaudited) (Parenthetical) - $ / shares	Apr. 30, 2019	Oct. 31, 2018
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	125,000,000	125,000,000
Preferred stock, issued and outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	2,000,000,000	2,000,000,000
Common stock, issued and outstanding (in shares)	317,000,000	318,000,000
Treasury Stock (in Shares)	9,000	0

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Cash flows from operating activities
Net income (loss)	$ 686	$ (115)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	107	101
Share-based compensation	40	43
Deferred taxes	(272)	(13)
Excess and obsolete inventory related charges	7	17
Other non-cash expense, net	2	2
Changes in assets and liabilities:
Accounts receivable	(17)	(21)
Inventory	(21)	(34)
Accounts payable	(8)	(14)
Employee compensation and benefits	(13)	(7)
Change in assets and liabilities due to Tax Act	0	533
Other assets and liabilities	(46)	26
Net cash provided by operating activities	465	518
Cash flows from Investing activities:
Investments in property, plant and equipment	(78)	(108)
Payment to acquire fair value investment	(18)	(1)
Payments in exchange for convertible note	(2)	(2)
Acquisitions of businesses and intangible assets, net of cash acquired	(248)	(7)
Net cash used in investing activities	(346)	(118)
Cash flows from financing activities:
Issuance of common stock under employee stock plans	33	36
Payment of taxes related to net share settlement of equity awards	(14)	(29)
Payment of dividends	(104)	(96)
Purchase of non-controlling interest	(4)	0
Proceeds from revolving credit facility	0	356
Repayment of debt and revolving credit facility	0	(251)
Treasury stock repurchases	(125)	(93)
Net cash used in financing activities	(214)	(77)
Effect of exchange rate movements	2	9
Net increase (decrease) in cash, cash equivalents and restricted cash	(93)	332
Cash, cash equivalents and restricted cash at the beginning of the period	2,254	2,686
Cash, cash equivalents and restricted cash at the end of the period	2,161	3,018
Supplemental cash flow information:
Income tax paid, net	104	48
Interest payments	36	43
Non-cash changes in investments in property, plant and equipment increase (decrease)	$ (23)	$ (21)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENT OF EQUITY - USD ($) shares in Thousands, $ in Millions	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings (Accumulated Deficit)	Accumulated Other Comprehensive Income (Loss)	Total Stockholder's Equity	Non-controlling Interest
Beginning Treasury Stock, Shares at Oct. 31, 2017				0
Beginning Treasury Stock, Value at Oct. 31, 2017				$ 0
Beginning Balance (in Shares) at Oct. 31, 2017		321,975
Beginning Balance at Oct. 31, 2017	$ 4,835	$ 3	$ 5,300		$ (126)	$ (346)	$ 4,831	$ 4
Components of comprehensive income, net of tax
Net income (loss)	(115)				(115)		(115)
Other comprehensive income	36					36	36
Total comprehensive income (loss), net of tax	(79)						(79)
Cash dividends declared	(96)				(96)		(96)
Share-based awards issued, net of tax (in shares)		1,688
Share-based awards issued	7		7				7
Repurchase of common stock (in shares)				(1,348)
Repurchase of common stock	(93)			$ (93)			(93)
Retirement of treasury shares (in shares)		(1,348)		(1,348)
Retirement of treasury shares	0	$ 0	(18)	$ (93)	(75)		0
Share-based compensation	43		43				43
Ending Treasury Stock, Shares at Apr. 30, 2018				0
Ending Treasury Stock, Value at Apr. 30, 2018				$ 0
Ending Balance (in Shares) at Apr. 30, 2018		322,315
Ending Balance at Apr. 30, 2018	4,617	$ 3	5,332		(412)	(310)	4,613	4
Beginning Treasury Stock, Shares at Jan. 31, 2018				(37)
Beginning Treasury Stock, Value at Jan. 31, 2018				$ (3)
Beginning Balance (in Shares) at Jan. 31, 2018		322,684
Beginning Balance at Jan. 31, 2018	4,526	$ 3	5,320		(529)	(269)	4,522	4
Components of comprehensive income, net of tax
Net income (loss)	205				205		205
Other comprehensive income	(41)					(41)	(41)
Total comprehensive income (loss), net of tax	164						164
Cash dividends declared	(48)				(48)		(48)
Share-based awards issued, net of tax (in shares)		342
Share-based awards issued	9		9				9
Repurchase of common stock (in shares)				(674)
Repurchase of common stock	(46)			$ (46)			(46)
Retirement of treasury shares (in shares)		(711)		(711)
Retirement of treasury shares	0	$ 0	(9)	$ (49)	(40)		0
Share-based compensation	12		12				12
Ending Treasury Stock, Shares at Apr. 30, 2018				0
Ending Treasury Stock, Value at Apr. 30, 2018				$ 0
Ending Balance (in Shares) at Apr. 30, 2018		322,315
Ending Balance at Apr. 30, 2018	4,617	$ 3	5,332		(412)	(310)	4,613	4
Cumulative Effect of New Accounting Principle in Period of Adoption	26				33	(7)	26
Beginning Treasury Stock, Shares at Oct. 31, 2018				0
Beginning Treasury Stock, Value at Oct. 31, 2018	0			$ 0
Beginning Balance (in Shares) at Oct. 31, 2018		317,715
Beginning Balance at Oct. 31, 2018	4,571	$ 3	5,308		(336)	(408)	4,567	4
Components of comprehensive income, net of tax
Net income (loss)	686				686		686
Other comprehensive income	17					17	17
Total comprehensive income (loss), net of tax	703						703
Change in non-controlling interest increase (decrease)	(4)							(4)
Cash dividends declared	(104)				(104)		(104)
Share-based awards issued, net of tax (in shares)		1,327
Share-based awards issued	18		18				18
Repurchase of common stock (in shares)				(1,766)
Repurchase of common stock	(125)			$ (125)			(125)
Retirement of treasury shares (in shares)		(1,757)		(1,757)
Retirement of treasury shares	0	$ 0	(23)	$ (124)	(101)		0
Share-based compensation	40		40				40
Ending Treasury Stock, Shares at Apr. 30, 2019				(9)
Ending Treasury Stock, Value at Apr. 30, 2019	1			$ (1)
Ending Balance (in Shares) at Apr. 30, 2019		317,285
Ending Balance at Apr. 30, 2019	5,125	$ 3	5,343		178	(398)	5,125	0
Beginning Treasury Stock, Shares at Jan. 31, 2019				0
Beginning Treasury Stock, Value at Jan. 31, 2019				$ 0
Beginning Balance (in Shares) at Jan. 31, 2019		317,533
Beginning Balance at Jan. 31, 2019	5,036	$ 3	5,324		90	(381)	5,036	0
Components of comprehensive income, net of tax
Net income (loss)	182				182		182
Other comprehensive income	(17)					(17)	(17)
Total comprehensive income (loss), net of tax	165						165
Cash dividends declared	(52)				(52)		(52)
Share-based awards issued, net of tax (in shares)		381
Share-based awards issued	10		10				10
Repurchase of common stock (in shares)				(638)
Repurchase of common stock	(50)			$ (50)			(50)
Retirement of treasury shares (in shares)		(629)		(629)
Retirement of treasury shares	0	$ 0	(7)	$ (49)	(42)		0
Share-based compensation	16		16				16
Ending Treasury Stock, Shares at Apr. 30, 2019				(9)
Ending Treasury Stock, Value at Apr. 30, 2019	1			$ (1)
Ending Balance (in Shares) at Apr. 30, 2019		317,285
Ending Balance at Apr. 30, 2019	$ 5,125	$ 3	$ 5,343		$ 178	$ (398)	$ 5,125	$ 0

CONDENSED CONSOLIDATE STATEMENT

CONDENSED CONSOLIDATE STATEMENT OF EQUITY - (PARENTHETICAL) - $ / shares	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Statement of Stockholders' Equity [Abstract]
Common Stock, Dividends, Per Share, Declared	$ 0.164	$ 0.149	$ 0.328	$ 0.298

OVERVIEW, BASIS OF PRESENTATION

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Notes)	6 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
OVERVIEW AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2019 and 2018 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2018 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 . In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2019 and October 31, 2018 , condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2019 and 2018 , condensed consolidated statement of operations for the three and six months ended April 30, 2019 and 2018 , condensed consolidated statement of cash flows for the six months ended April 30, 2019 and 2018 and condensed consolidated statement of equity for the three and six months ended April 30, 2019 and 2018 . Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, share-based compensation, retirement and post-retirement benefit plan assumptions, goodwill and purchased intangible assets and accounting for income taxes. Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $27 million and is lower than the carrying value by approximately $15 million as of April 30, 2019 and October 31, 2018 , respectively. The change in the fair value over carrying value in the six months ended April 30, 2019 is primarily due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments. Revenue Recognition . We enter into agreements to sell products (hardware and/or software), services and other arrangements (multiple element arrangements) that include combinations of products and services. We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 2, "New Accounting Pronouncements" and Note 3, "Revenue" for additional information on revenue recognition. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled to in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses sold by us, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded. Revenue from services includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. These contracts are recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls are recognized to revenue at the time a service is performed. We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis. Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Stand-alone selling prices are determined at contract inception for each distinct good or service in the contract and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations. Certain of our revenue relate to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

NEW ACCOUNTING PRONOUNCEMENTS (

NEW ACCOUNTING PRONOUNCEMENTS (Notes)	6 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
NEW ACCOUNTING PRONOUNCEMENTS	NEW ACCOUNTING PRONOUNCEMENTS Accounting Pronouncements Not Yet Adopted There were no changes to the new accounting pronouncements not yet adopted as described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 except for the following: In February 2016, the Financial Accounting Standards Board ("FASB") issued guidance which amends the existing accounting standards for leases. Consistent with existing guidance, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will depend on its classification. Under the new guidance, a lessee will be required to recognize right-of-use assets and lease liabilities on the balance sheet. In July 2018, the FASB clarified two requirements in the new leases standard. The FASB decided to provide another transition method by allowing companies to initially apply the new leases standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. In addition, the FASB decided to provide lessors with a practical expedient to not separate nonlease components from the associated lease component, similar to the expedient provided for lessees. In December 2018, the FASB update clarified application of Accounting Standard Codification ("ASC") Topic 842, Leases. The new guidance is effective for us beginning November 1, 2019, and for interim periods within that year. Early adoption is permitted, and we will be required to adopt using a modified retrospective approach. We are evaluating the impact of this guidance on our consolidated financial statements and disclosures. Recently Adopted Accounting Pronouncements In May 2014, the FASB issued new revenue recognition guidance, ASC Topic 606, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. The objective of the new revenue standard is to significantly enhance comparability and clarify principles of revenue recognition practices across entities, industries, jurisdictions and capital markets. Under the new guidance, there are specific criteria to determine if a performance obligation should be recognized over time or at a point in time. On November 1, 2018, we adopted ASC 606 using the modified retrospective approach only to contracts not completed as of this date. Results for reporting periods after November 1, 2018 are presented under ASC 606, while prior period amounts were not adjusted and continue to be reported in accordance with ASC Topic 605, Revenue Recognition . We recorded a net increase to beginning retained earnings of $23 million as of November 1, 2018 due to the cumulative impact of adopting ASC 606. The impact to beginning retained earnings is primarily due to an increase in contract assets (unbilled accounts receivable), a reduction in inventory and a reduction in contract liabilities (deferred revenue). The net increase in retained earnings and resulting changes in assets and liabilities was mainly driven by the change in timing of the recognition of revenue from the fulfillment of separate performance obligations as control transfers to the customer. Had we continued to use the revenue recognition guidance in effect prior to 2018, no material changes would have resulted to the consolidated statements of income, comprehensive income, or cash flows for the three and six months ended April 30, 2019 . Refer to Note 1, for a description of the company’s revenue recognition policies and Note 3, "Revenue" for the disclosures required by the standard. As of November 1, 2018, we elected to early adopt new accounting guidance which amends reporting comprehensive income to allow a reclassification from accumulated other comprehensive income ("AOCI") to retained earnings for the deferred taxes previously recorded in AOCI that exceed the current federal tax rate of 21 percent resulting from the enacted corporate tax rate in the U.S. Tax Cuts and Jobs Act ("the Tax Act"). The adoption of this guidance resulted in a reclassification of $7 million from AOCI to beginning retained earnings on our condensed consolidated balance sheet. As of November 1, 2018, we adopted new accounting guidance which eliminates the exception in ASC 740, Income Taxes against immediate recognition of income tax consequences of intra-entity transfers of assets other than inventory. The amendment in this update should be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of period of adoption. We recorded a net decrease in beginning retained earnings of $2 million as of November 1, 2018 due to removing unamortized tax expense previously deferred. As of November 1, 2018, we adopted new accounting guidance which addresses certain aspects of recognition, measurement, presentation and disclosure of financial instruments and also the related guidance which addresses technical corrections and improvements to this guidance. The guidance requires entities to measure equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize any changes in fair value in net income. The total impact of adoption to our condensed consolidated balance sheet was an increase of $7 million to long-term investments and a net increase of $5 million to beginning retained earnings. The following table summarizes the impacts of recently adopted accounting pronouncements on our condensed consolidated balance sheet as of November 1, 2018: October 31, Impact of Adopting New November 1, As Reported Revenue Recognition Guidance Tax Effects on Items in AOCI Guidance Intra-Entity Tax Guidance Investments Valuation Guidance As Adopted (in millions) ASSETS Current assets: Cash and cash equivalents $ 2,247 $ — $ — $ — $ — $ 2,247 Accounts receivable, net 776 24 — — — 800 Inventory 638 (10 ) — — — 628 Other current assets 187 3 — — — 190 Total current assets 3,848 17 — — — 3,865 Property, plant and equipment, net 822 — — — — 822 Goodwill 2,973 — — — — 2,973 Other intangible assets, net 491 — — — — 491 Long-term investments 68 — — — 7 75 Other assets 339 (3 ) — (2 ) (2 ) 332 Total assets $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 340 $ — $ — $ — $ — $ 340 Employee compensation and benefits 304 — — — — 304 Deferred revenue 324 (11 ) — — — 313 Other accrued liabilities 203 — — — — 203 Total current liabilities 1,171 (11 ) — — — 1,160 Long-term debt 1,799 — — — — 1,799 Retirement and post-retirement benefits 239 — — — — 239 Other long-term liabilities 761 2 — — — 763 Total liabilities 3,970 (9 ) — — — 3,961 Total equity: Stockholders’ equity: Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding — — — — — — Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued 3 — — — — 3 Additional paid-in-capital 5,308 — — — — 5,308 Accumulated deficit (336 ) 23 7 (2 ) 5 (303 ) Accumulated other comprehensive loss (408 ) — (7 ) — — (415 ) Total stockholders' equity 4,567 23 — (2 ) 5 4,593 Non-controlling interest 4 — — — — 4 Total equity 4,571 23 — (2 ) 5 4,597 Total liabilities and equity $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 As of November 1, 2018, we adopted new accounting guidance which requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: April 30, October 31 2019 2018 (in millions) Cash and cash equivalents $ 2,155 $ 2,247 Restricted cash included in other assets 6 7 Total cash, cash equivalents and restricted cash $ 2,161 $ 2,254 As of November 1, 2018, we adopted new accounting guidance which requires employers that present a measure of operating income in their statements of operations to include only the service cost component of net periodic postretirement benefit cost in operating expenses. The service cost component of net periodic pension and postretirement benefit cost should be presented in the same operating expense line items as other employee compensation costs arising from services rendered during the period. The other components of net periodic pension and postretirement benefit costs, including interest costs, expected return on assets, amortization of prior service cost/credit and actuarial gains/losses, and settlement and curtailment effects, are to be included separately and outside of any subtotal of operating income. The adoption of this guidance resulted in a reclassification of income from our income from operations to other income (expense) on our consolidated statement of operations of approximately $3 million and $5 million in the three and six months ended April 30, 2019 , respectively and approximately $5 million and $15 million in the three and six months ended April 30, 2018 , respectively. As adoption is required to be on a retrospective basis, we have recast our historical condensed consolidated statements of operations and segment information to conform to current year presentation. Other amendments to GAAP in the U.S. that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our consolidated financial statements upon adoption.

REVENUE (Notes)

REVENUE (Notes)	6 Months Ended
	Apr. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue from Contract with Customer [Text Block]	REVENUE The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Three Months Ended April 30, 2019 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Revenue by Region Americas $ 145 $ 120 $ 168 $ 433 Europe 125 97 132 354 Asia Pacific 259 37 155 451 Total $ 529 $ 254 $ 455 $ 1,238 Six Months Ended April 30, 2019 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Revenue by Region Americas $ 313 $ 229 $ 324 $ 866 Europe 289 188 260 737 Asia Pacific 534 72 313 919 Total $ 1,136 $ 489 $ 897 $ 2,522 The following table presents the company’s total revenue disaggregated by end markets and by revenue type: Three Months Ended Six Months Ended April 30, 2019 April 30, 2019 (in millions) Revenue by End Markets Pharmaceutical and Biotechnology $ 371 $ 762 Chemical and Energy 300 608 Diagnostics and Clinical 193 380 Food 114 243 Academia and Government 114 230 Environmental and Forensics 146 299 Total $ 1,238 $ 2,522 Revenue by Type Instrumentation $ 491 $ 1,058 Non-instrumentation and other 747 1,464 Total $ 1,238 $ 2,522 Revenue by region is based on the ship to location of the customer. Revenue by end market is determined by the market indicator of the customer and by customer type. Instrumentation revenue includes sales from instruments, remarketed instruments and third-party products. Non-instrumentation and other revenue includes sales from contract and per incident services, our companion diagnostics and our nucleic acid solutions businesses as well as sales from spare parts, consumables, reagents, vacuum pumps, subscriptions, software licenses and associated services. Contract Balances Contract Assets Contract assets (unbilled accounts receivable) primarily relate to the company's right to consideration for work completed but not billed at the reporting date. The unbilled receivables are reclassified to trade receivables when billed to customers. Contracts assets are generally classified as current assets and are included in "Accounts receivable, net" in the condensed consolidated balance sheet. The balance of contract assets as of April 30, 2019 and as of the date of adoption of ASC 606 were $86 million and $57 million , respectively. The increase in unbilled receivables during the six months ended April 30, 2019 is a result of recognition of revenue upon the transfer of the control to the customer. In some instances transfer of control is prior to invoicing the customers and excluding amounts transferred to trade receivables during the period amounted to $29 million . Contract Liabilities The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2019 : Contract Liabilities (in millions) Ending balance as of October 31, 2018 $ 367 Impact of adoption of new revenue recognition guidance (11 ) Net revenue deferred in the period 224 Revenue recognized that was included in the contract liability balance at the beginning of the period (191 ) Change in deferrals from customer cash advances, net of revenue recognized 2 Contract liabilities acquired in business combinations 2 Currency translation and other adjustments 1 Ending balance as of April 30, 2019 $ 394 Contract liabilities primarily relate to multiple element arrangements for which billing has occurred but transfer of control of all elements to the customer has either partially or not occurred at the balance sheet date. This includes cash received from customers for products and related installation and services in advance of the transfer of control. Contract liabilities are classified as either current in deferred revenue or long-term in other long-term liabilities in the condensed consolidated balance sheet based on the timing of when we expect to complete our performance obligation. Contract Costs Incremental costs of obtaining a contract with a customer are recognized as an asset if it expects the benefit of those costs to be longer than one year. We have determined that certain sales incentive programs meet the requirements to be capitalized. The change in total capitalized costs to obtain a contract was immaterial during the period and are included in other current and long-term assets on the condensed consolidated balance sheet. We have applied the practical expedient to expense costs as incurred for costs to obtain a contract with a customer when the amortization period would have been one year or less. These costs include the company's internal sales force compensation program, as we have determined that annual compensation is commensurate with annual sales activities. Transaction Price Allocated to the Remaining Performance Obligations We have applied the practical expedient in ASC 606-10-50-14 and have not disclosed information about transaction price allocated to remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized for remaining performance obligations that have an original term of more than one year, as of April 30, 2019 , was $174 million , the majority of which is expected to be recognized over the next 12 months. Remaining performance obligations primarily include extended warranty, customer manufacturing contracts, and software maintenance contracts and revenue associated with lease arrangements.

SHARE-BASED COMPENSATION (Notes

SHARE-BASED COMPENSATION (Notes)	6 Months Ended
	Apr. 30, 2019
Share-based Compensation [Abstract]
SHARE-BASED COMPENSATION	SHARE-BASED COMPENSATION Agilent accounts for share-based awards in accordance with the provisions of the authoritative accounting guidance which requires the measurement and recognition of compensation expense for all share-based payment awards made to our employees and directors including restricted stock units, employee stock purchases made under our employee stock purchase plan (“ESPP”) and performance share awards granted to selected members of our senior management under the long-term performance plan (“LTPP”) based on estimated fair values. Participants in the LTPP are entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets are met. Certain LTPP awards are generally designed to meet the criteria of a performance award with the performance metrics and peer group comparison based on the Total Stockholders’ Return (“TSR”) set at the beginning of the performance period. Effective November 1, 2015, the Compensation Committee of the Board of Directors approved another type of performance stock award, for the company's executive officers and other key employees. Participants in this program are also entitled to receive shares of the company's stock after the end of a three-year period, if specified performance targets over the three-year period are met. The performance target for grants made beginning 2017 and later were based on Earnings Per Share ("EPS"). The performance targets for the LTPP-EPS grants for year 2 and year 3 of the performance period are set in the first quarter of year 2 and year 3, respectively. All LTPP awards granted after November 1, 2015, are subject to a one-year post-vest holding period. The final LTPP award may vary from zero to 200 percent of the target award. The maximum award value for awards granted in 2017 cannot exceed 300 percent of the grant date target value. We consider the dilutive impact of these programs in our diluted net income per share calculation only to the extent that the performance conditions are expected to be met. Restricted stock units generally vest, with some exceptions, at a rate of 25 percent per year over a period of four years from the date of grant. The impact on our results for share-based compensation was as follows: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Cost of products and services $ 4 $ 3 $ 9 $ 10 Research and development 2 1 4 4 Selling, general and administrative 10 8 27 29 Total share-based compensation expense $ 16 $ 12 $ 40 $ 43 At April 30, 2019 and October 31, 2018 , there was no share-based compensation capitalized within inventory. The following assumptions were used to estimate the fair value of awards granted. Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 LTPP: Volatility of Agilent shares 22% 21% 22% 21% Volatility of selected peer-company shares 15%-66% 14%-66% 15%-66% 14%-66% Pair-wise correlation with selected peers 30% 32% 30% 32% Post-vest holding restriction discount for all executive awards 5.0% 4.8% 5.0% 4.8% Shares granted under the LTPP (TSR) were valued using a Monte Carlo simulations model. The Monte Carlo simulation fair value model requires the use of highly subjective and complex assumptions, including the price volatility of the underlying stock. For the volatility of our LTPP (TSR) grants, we used our own historical stock price volatility. The ESPP allows eligible employees to purchase shares of our common stock at 85 percent of the price at purchase and uses the purchase date to establish the fair market value. The estimated fair value of restricted stock units and LTPP (EPS) awards is determined based on the market price of Agilent’s common stock on the date of grant adjusted for expected dividend yield. The compensation cost for LTPP (EPS) reflects the cost of awards that are probable to vest at the end of the performance period. All awards granted in 2016 and thereafter to our senior management employees have a one-year post-vest holding restriction. The estimated discount associated with post-vest holding restrictions is calculated using the Finnerty model (see table above). The model calculates the potential lost value if the employee were able to sell the shares during the lack of marketability period, instead of being required to hold the shares. The model used the same historical stock price volatility and dividend yield assumption used for the Monte Carlo simulations model and an expected dividend yield to compute the discount.

INCOME TAXES (Notes)

INCOME TAXES (Notes)	6 Months Ended
	Apr. 30, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES For the three and six months ended April 30, 2019 , the company's income tax expense was $36 million with an effective tax rate of 16.5 percent and an income tax benefit of $220 million with an effective tax rate of (47.2) percent , respectively. For the six months ended April 30, 2019 , our effective tax rate and the resulting provision for income taxes were significantly impacted by the discrete benefit of $299 million related to the restructuring and extension of the company’s tax incentive in Singapore. The income tax provision for the three and six months ended April 30, 2019 also includes the excess tax benefits from stock-based compensation of $3 million and $7 million , respectively. For the three and six months ended April 30, 2018 , the company's income tax expense was $22 million with an effective tax rate of 9.7 percent and $575 million with an effective tax rate of 125.0 percent , respectively. The effective tax rate and the provision for income taxes were significantly impacted by a discrete charge of $533 million related to the enactment of the Tax Act. The income taxes provision for the three and six months ended April 30, 2018 also included the excess tax benefits from stock-based compensation of $7 million and $18 million , respectively. 2017 U.S. Tax Reform - Tax Cuts and Jobs Act On December 22, 2017, the Tax Act was enacted into law. The Tax Act enacted significant changes affecting our fiscal year 2018, including, but not limited to, (1) reducing the U.S. federal corporate tax rate and (2) imposing a one-time transition tax on certain unrepatriated earnings of foreign subsidiaries that had not been previously taxed in the U.S. The Tax Act also establishes new tax provisions affecting our fiscal year 2019, including, but not limited to, (1) creating a new provision designed to tax global intangible low-tax income (“GILTI”); (2) generally eliminating U.S. federal taxes on dividends from foreign subsidiaries; (3) eliminating the corporate alternative minimum tax (“AMT”); (4) creating the base erosion anti-abuse tax (“BEAT”); (5) establishing a deduction for foreign derived intangible income ("FDII"); (6) repealing the domestic production activity deduction; and (7) establishing new limitations on deductible interest expense and certain executive compensation. GILTI: The Tax Act subjects a U.S. corporation to tax on its GILTI. U.S. GAAP allows companies to make an accounting policy election to either (1) treat taxes due on future GILTI inclusions in the U.S. taxable income as a current-period expense when incurred (“period cost method”) or (2) factoring such amounts into a company’s measurement of its deferred taxes (“deferred method”). We have completed our analysis and elected to treat GILTI as a “current period cost”. In the U.S., tax years remain open back to the year 2015 for federal income tax purposes and the year 2000 for significant states. In other major jurisdictions where the company conducts business, the tax years generally remain open back to the year 2001. There were no substantial changes from our 2018 Annual Report on Form 10-K to the status of the open tax years in the first six months of fiscal year 2019. It is reasonably possible there could be significant changes to our unrecognized tax benefits in the next twelve months due to either the expiration of a statute of limitation or a tax audit settlement. Given the number of years and numerous matters that remain subject to examination in various tax jurisdictions, management is unable to estimate the range of possible changes to the balance of our unrecognized tax benefits. The company will continue to assess the impact of the further guidance from federal and state tax authorities on its business and consolidated financial statements. Any future adjustments will be recognized as discrete income tax expense or benefit in the period the adjustments are determined.

NET INCOME PER SHARE (Notes)

NET INCOME PER SHARE (Notes)	6 Months Ended
	Apr. 30, 2019
Earnings Per Share [Abstract]
NET INCOME PER SHARE	NET INCOME PER SHARE The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Numerator: Net income (loss) $ 182 $ 205 $ 686 $ (115 ) Denominator: Basic weighted-average shares 317 322 318 323 Potential common shares— stock options and other employee stock plans 4 4 4 — Diluted weighted-average shares 321 326 322 323 The dilutive effect of share-based awards is reflected in diluted net income per share by application of the treasury stock method, which includes consideration of unamortized share-based compensation expense and the dilutive effect of in-the-money options and non-vested restricted stock units. Under the treasury stock method, the amount the employee must pay for exercising stock options and unamortized share-based compensation expense collectively are assumed proceeds to be used to repurchase hypothetical shares. An increase in the fair market value of the company's common stock can result in a greater dilutive effect from potentially dilutive awards. We exclude stock options with exercise prices greater than the average market price of our common stock from the calculation of diluted earnings per share because their effect would be anti-dilutive. In addition, we exclude from the calculation of diluted earnings per share stock options, ESPP, LTPP and restricted stock awards whose combined exercise price and unamortized fair value were greater than the average market price of our common stock because their effect would also be anti-dilutive. For the three and six months ended April 30, 2019 , no potential common shares were excluded from the calculation of diluted earnings per share. For the three months ended April 30, 2018 , 96,800 potential common shares outstanding were excluded from the calculation of diluted earnings per share. For the six months ended April 30, 2018 , the diluted net loss per share was the same as basic net loss per share as the effects of all 6.6 million potential common shares outstanding would have been anti-dilutive.

INVENTORY (Notes)

INVENTORY (Notes)	6 Months Ended
	Apr. 30, 2019
Inventory, Net [Abstract]
INVENTORY	INVENTORY April 30, October 31, (in millions) Finished goods $ 401 $ 386 Purchased parts and fabricated assemblies 256 252 Inventory $ 657 $ 638

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS (Notes)	6 Months Ended
	Apr. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2019 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2018 $ 803 $ 1,607 $ 563 $ 2,973 Foreign currency translation impact — (2 ) (1 ) (3 ) Goodwill arising from acquisitions and adjustments 153 (11 ) — 142 Goodwill as of April 30, 2019 $ 956 $ 1,594 $ 562 $ 3,112 The components of other intangible assets as of April 30, 2019 and October 31, 2018 are shown in the table below: Purchased Other Intangible Assets Gross Carrying Amount Accumulated Amortization and Impairments Net Book Value (in millions) As of October 31, 2018 Purchased technology $ 947 $ 683 $ 264 Trademark/Tradename 151 88 63 Customer relationships 107 63 44 Third-party technology and licenses 28 19 9 Total amortizable intangible assets 1,233 853 380 In-Process R&D 111 — 111 Total $ 1,344 $ 853 $ 491 As of April 30, 2019 Purchased technology $ 1,026 $ 720 $ 306 Trademark/Tradename 153 95 58 Customer relationships 127 71 56 Third-party technology and licenses 28 21 7 Total amortizable intangible assets 1,334 907 427 In-Process R&D 111 — 111 Total $ 1,445 $ 907 $ 538 On November 14, 2018, we acquired 100 percent of the stock of ACEA Biosciences (“ACEA”), a developer of cell analysis tools, for approximately $250 million in cash. The financial results of ACEA have been included within our financial results from the date of the close. The purchase accounting for this acquisition is substantially complete and will be finalized during 2019, as we assess the tax impact and finalize the intangibles valuation of the acquisition. During the six months ended April 30, 2019 , we recorded additions to goodwill of $153 million related primarily to the ACEA acquisition within the life sciences and applied markets business. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. During the six months ended April 30, 2019 , we recorded additions to other intangible assets of $102 million related to the ACEA acquisition. In general, for United States federal tax purposes, goodwill from asset purchases is deductible, however any goodwill created as part of a stock acquisition is not deductible. Each quarter we review the events and circumstances to determine if impairment of indefinite-lived intangible assets and goodwill is indicated. There were no indicators of impairments of indefinite-lived intangible assets or goodwill during the three and six months ended April 30, 2019 and 2018 , respectively. Amortization expense of intangible assets was $26 million and $55 million for the three and six months ended April 30, 2019 , respectively. Amortization expense of intangible assets was $26 million and $52 million for the three and six months ended and April 30, 2018 , respectively. Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2019 and for each of the five succeeding fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2019 $ 53 2020 $ 94 2021 $ 81 2022 $ 65 2023 $ 55 2024 $ 46 Thereafter $ 33

FAIR VALUE MEASUREMENTS (Notes)

FAIR VALUE MEASUREMENTS (Notes)	6 Months Ended
	Apr. 30, 2019
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The authoritative guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, we consider the principal or most advantageous market and assumptions that market participants would use when pricing the asset or liability. Fair Value Hierarchy The guidance establishes a fair value hierarchy that prioritizes the use of inputs used in valuation techniques into three levels. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. There are three levels of inputs that may be used to measure fair value: Level 1 - applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities. Level 2 - applies to assets or liabilities for which there are inputs other than quoted prices included within level 1 that are observable, either directly or indirectly, for the asset or liability such as: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in less active markets; or other inputs that can be derived principally from, or corroborated by, observable market data. Level 3 - applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities. Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Financial assets and liabilities measured at fair value on a recurring basis as of April 30, 2019 were as follows: Fair Value Measurement at April 30, 2019 Using April 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,229 $ 1,229 $ — $ — Derivative instruments (foreign exchange contracts) 6 — 6 — Long-term Trading securities 31 31 — — Other investments 24 — 24 — Total assets measured at fair value $ 1,290 $ 1,260 $ 30 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 2 $ — $ 2 $ — Long-term Deferred compensation liability 31 — 31 — Total liabilities measured at fair value $ 33 $ — $ 33 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2018 were as follows: Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,355 $ 1,355 $ — $ — Derivative instruments (foreign exchange contracts) 16 — 16 — Long-term Trading securities 30 30 — — Total assets measured at fair value $ 1,401 $ 1,385 $ 16 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 35 $ — $ 35 $ — Our money market funds and trading securities are generally valued using quoted market prices and therefore are classified within level 1 of the fair value hierarchy. Our derivative financial instruments are classified within level 2, as there is not an active market for each hedge contract, but the inputs used to calculate the value of the instruments are tied to active markets. Our deferred compensation liability is classified as level 2 because, although the values are not directly based on quoted market prices, the inputs used in the calculations are observable. Other investments represent shares we own in a special fund that targets underlying investments of approximately 40 percent in debt securities and 60 percent in equity securities. It has been classified as level 2 because, although the shares of the fund are not traded on any active stock exchange, each of the individual underlying securities are and hence we have a readily determinable value for the underlying securities, from which we are able to determine the fair market value for the special fund itself. Trading securities, which is comprised of mutual funds, bonds and other similar instruments, other investments and deferred compensation liability are reported at fair value, with gains or losses resulting from changes in fair value recognized currently in net income. Certain derivative instruments are reported at fair value, with unrealized gains and losses, net of tax, included in accumulated other comprehensive loss within stockholders' equity. Realized gains and losses from the sale of these instruments are recorded in net income. Impairment of Investments. There were no impairments of investments for the three and six months ended April 30, 2019 and 2018 . Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis For the three and six months ended April 30, 2019 and 2018 , there were no impairments of long-lived assets held and used or long-lived assets held for sale. For the three and six months ended April 30, 2019 , there were no impairment or material change in fair value of non-marketable securities. As of April 30, 2019 and October 31, 2018 , the carrying amount of non-marketable equity securities without readily determinable fair values was $42 million and $23 million , respectively. Fair values for the non-marketable securities included in long-term investments on the condensed consolidated balance sheet were measured using Level 3 inputs because they are primarily equity stock issued by private companies without quoted market prices. To estimate the fair value of our non-marketable securities, we use the measurement alternative to record these investments at cost and to adjust for impairments and observable price changes (orderly transactions for the identical or a similar security from the same issuer) as and when it occurs.

DERIVATIVES (Notes)

DERIVATIVES (Notes)	6 Months Ended
	Apr. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVES	DERIVATIVES We are exposed to foreign currency exchange rate fluctuations and interest rate changes in the normal course of our business. As part of our risk management strategy, we use derivative instruments, primarily forward contracts, purchased options to hedge economic and/or accounting exposures resulting from changes in foreign currency exchange rates. Fair Value Hedges We are exposed to interest rate risk due to the mismatch between the interest expense we pay on our loans at fixed rates and the variable rates of interest we receive from cash, cash equivalents and other short-term investments. We have issued long-term debt in U.S. dollars at fixed interest rates based on the market conditions at the time of financing. The fair value of our fixed rate debt changes when the underlying market rates of interest change, and, in the past, we have used interest rate swaps to change our fixed interest rate payments to U.S. dollar LIBOR-based variable interest expense to match the floating interest income from our cash, cash equivalents and other short-term investments. As of April 30, 2019 , all interest rate swap contracts had either been terminated or had expired. On August 9, 2011, we terminated five interest rate swap contracts related to our 2020 senior notes that represented the notional amount of $500 million . The remaining gain to be amortized at April 30, 2019 was $5 million . All deferred gains from terminated interest rate swaps are being amortized over the remaining life of the 2020 senior notes. Cash Flow Hedges We enter into foreign exchange contracts to hedge our forecasted operational cash flow exposures resulting from changes in foreign currency exchange rates. These foreign exchange contracts, carried at fair value, have maturities between one and twelve months. These derivative instruments are designated and qualify as cash flow hedges under the criteria prescribed in the authoritative guidance and are assessed for effectiveness against the underlying exposure every reporting period. For open contracts as of April 30, 2019 and entered into prior to November 1, 2018, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales each period. For open contracts as of April 30, 2019 and entered into on or after November 1, 2018, changes in the time value of the foreign exchange contract are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the foreign exchange contract. The changes in fair value of the effective portion of the derivative instrument are recognized in accumulated other comprehensive income (loss). Amounts associated with cash flow hedges are reclassified to cost of sales in the condensed consolidated statement of operations when the forecasted transaction occurs. If it becomes probable that the forecasted transaction will not occur, the hedge relationship will be de-designated and amounts accumulated in other comprehensive income (loss) will be reclassified to other income (expense) in the current period. Changes in the fair value of the ineffective portion of derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations in the current period. We record the premium paid (time value) of an option on the date of purchase as an asset. For options designated as cash flow hedges, changes in the time value are excluded from the assessment of hedge effectiveness and are recognized in cost of sales over the life of the option contract. For the three and six months ended April 30, 2019 and 2018 ineffectiveness and gains and losses recognized in other income (expense) due to de-designation of cash flow hedge contracts were not significant. In July 2012, Agilent executed treasury lock agreements for $400 million in connection with future interest payments to be made on our 2022 senior notes issued on September 10, 2012. We designated the treasury lock as a cash flow hedge. The treasury lock contracts were terminated on September 10, 2012 and we recognized a deferred gain in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2022 senior notes. The remaining gain to be amortized related to the treasury lock agreements at April 30, 2019 was $1 million . In February 2016, Agilent executed three forward-starting pay fixed/receive variable interest rate swaps for the notional amount of $300 million in connection with future interest payments to be made on our 2026 senior notes issued on September 15, 2016. These derivative instruments were designated and qualified as cash flow hedges under the criteria prescribed in the authoritative guidance. The swap arrangements were terminated on September 15, 2016 with a payment of $10 million and we recognized this as a deferred loss in accumulated other comprehensive income which is being amortized to interest expense over the life of the 2026 senior notes. The remaining loss to be amortized related to the interest rate swap agreements at April 30, 2019 was $7 million . Other Hedges Additionally, we enter into foreign exchange contracts to hedge monetary assets and liabilities that are denominated in currencies other than the functional currency of our subsidiaries. These foreign exchange contracts are carried at fair value and do not qualify for hedge accounting treatment and are not designated as hedging instruments. Changes in value of the derivative instruments are recognized in other income (expense) in the condensed consolidated statement of operations, in the current period, along with the offsetting foreign currency gain or loss on the underlying assets or liabilities. Our use of derivative instruments exposes us to credit risk to the extent that the counterparties may be unable to meet the terms of the agreement. We do, however, seek to mitigate such risks by limiting our counterparties to major financial institutions which are selected based on their credit ratings and other factors. We have established policies and procedures for mitigating credit risk that include establishing counterparty credit limits, monitoring credit exposures, and continually assessing the creditworthiness of counterparties. A number of our derivative agreements contain threshold limits to the net liability position with counterparties and are dependent on our corporate credit rating determined by the major credit rating agencies. The counterparties to the derivative instruments may request collateralization, in accordance with derivative agreements, on derivative instruments in net liability positions. The aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position as of April 30, 2019 , was $1 million . The credit-risk-related contingent features underlying these agreements had not been triggered as of April 30, 2019 . There were 276 foreign exchange forward contracts open as of April 30, 2019 and designated as cash flow hedges. There were 145 foreign exchange forward contracts open as of April 30, 2019 not designated as hedging instruments. The aggregated notional amounts by currency and designation as of April 30, 2019 were as follows: Derivatives Designated as Cash Flow Hedges Derivatives Not Designated as Hedging Instruments Forward Contracts USD Forward Contracts USD Currency Buy/(Sell) Buy/(Sell) (in millions) Euro $ (57 ) $ 33 British Pound (56 ) 7 Canadian Dollar (30 ) (4 ) Australian Dollar 5 4 Malaysian Ringgit — (2 ) Japanese Yen (97 ) 14 Danish Krone — (4 ) Korean Won (50 ) (31 ) Singapore Dollar 17 (5 ) Swiss Franc — (7 ) Chinese Yuan Renminbi (57 ) (33 ) Polish Zloty — (3 ) Swedish Krona — (9 ) Other — (9 ) Totals $ (325 ) $ (49 ) Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of April 30, 2019 and October 31, 2018 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location April 30, October 31, Balance Sheet Location April 30, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 4 $ 11 Other accrued liabilities $ 1 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 2 $ 5 Other accrued liabilities $ 1 $ 4 Total derivatives $ 6 $ 16 $ 2 $ 5 The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) $ 4 $ 5 $ (2 ) $ (5 ) Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ — $ (5 ) $ 5 $ (5 ) Gain on time value of forward contracts recorded in cost of sales $ 1 $ — $ 2 $ — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ 1 $ (5 ) $ (2 ) $ 1 At April 30, 2019 , the estimated amount of existing net gain that is expected to be reclassified from accumulated other comprehensive loss to cost of sales within the next twelve months is $5 million .

RETIREMENT PLANS AND POST RETIR

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Notes)	6 Months Ended
	Apr. 30, 2019
Defined Benefit Plan [Abstract]
RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS	RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS Components of net periodic costs. For the three and six months ended April 30, 2019 and 2018 , our net pension and post retirement benefit costs were comprised of the following: Three Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement Benefit Plans 2019 2018 2019 2018 2019 2018 (in millions) Service cost—benefits earned during the period $ — $ — $ 4 $ 4 $ — $ — Interest cost on benefit obligation 5 4 3 3 1 1 Expected return on plan assets (7 ) (7 ) (11 ) (12 ) (1 ) (2 ) Amortization: Actuarial losses — — 9 8 1 2 Prior service credits — — — — (2 ) (2 ) Total net plan costs $ (2 ) $ (3 ) $ 5 $ 3 $ (1 ) $ (1 ) Six Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2019 2018 2019 2018 2019 2018 (in millions) Service cost—benefits earned during the period $ — $ — $ 10 $ 10 $ — $ — Interest cost on benefit obligation 10 8 6 6 1 2 Expected return on plan assets (14 ) (14 ) (22 ) (23 ) (2 ) (4 ) Amortization: Actuarial losses — — 18 15 2 4 Prior service credits — — — — (4 ) (4 ) Total net plan costs $ (4 ) $ (6 ) $ 12 $ 8 $ (3 ) $ (2 ) Settlements gains $ — $ — $ — $ (5 ) $ — $ — The service cost component is recorded in cost of sales and operating expenses in the condensed consolidated statement of operations. All other cost components are recorded in other income (expense), net in the condensed consolidated statement of operations. We made no contributions to our U.S. defined benefit plans during the three and six months ended April 30, 2019 , respectively. We contributed $5 million and $11 million to our non-U.S. defined benefit plans during the three and six months ended April 30, 2019 , respectively. We made no contributions to our U.S. defined benefit plans during the three and six months ended April 30, 2018 , respectively. We contributed $5 million and $11 million to our non-U.S. defined benefit plans during the three and six months ended April 30, 2018 . We do not expect to contribute to our U.S. defined benefit plans during the remainder of 2019 and we expect to contribute $15 million to our non-U.S. defined benefit plans during the remainder of 2019 . Japanese Welfare Pension Insurance Law . In Japan, Agilent has employees' pension fund plans, which are defined benefit pension plans established under the Japanese Welfare Pension Insurance Law ("JWPIL"). The plans are composed of (a) a substitutional portion based on the pay-related part of the old-age pension benefits prescribed by JWPIL (similar to social security benefits in the United States) and (b) a corporate portion based on a contributory defined benefit pension arrangement established at the discretion of the company. During the three months ended January 31, 2017 , Agilent received government approval and returned the substitutional portion of Japan's pension plan to the Japanese government, as allowed by the JWPIL. The initial transfer resulted in a net gain of $32 million . In the first quarter of fiscal year 2018, after the Japanese government’s final review of our initial payment, we received a refund of $5 million which was recorded as a settlement gain.

WARRANTIES AND CONTINGENCIES (N

WARRANTIES AND CONTINGENCIES (Notes)	6 Months Ended
	Apr. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
WARRANTIES AND CONTINGENCIES	WARRANTIES AND CONTINGENCIES Warranties We accrue for standard warranty costs based on historical trends in warranty charges as a percentage of net product shipments. The accrual is reviewed regularly and periodically adjusted to reflect changes in warranty cost estimates. Estimated warranty charges are recorded within cost of products at the time products are sold. The standard warranty accrual balances are held in other accrued and other long-term liabilities on our condensed consolidated balance sheet. Our standard warranty terms typically extend to one year from the date of delivery, depending on the product. A summary of the standard warranty accrual activity is shown in the table below: Six Months Ended April 30, 2019 2018 (in millions) Beginning balance as of November 1, $ 35 $ 34 Accruals for warranties including change in estimate 27 25 Settlements made during the period (30 ) (26 ) Ending balance as of April 30, $ 32 $ 33 Accruals for warranties due within one year $ 32 $ 33 Contingencies We are involved in lawsuits, claims, investigations and proceedings, including, but not limited to, intellectual property, commercial, real estate, environmental and employment matters, which arise in the ordinary course of business. There are no matters pending that we currently believe are probable and reasonably possible of having a material impact to our business, consolidated financial condition, results of operations or cash flows.

SHORT-TERM DEBT (Notes)

SHORT-TERM DEBT (Notes)	6 Months Ended
	Apr. 30, 2019
Short-term Debt [Abstract]
SHORT-TERM DEBT	SHORT-TERM DEBT Credit Facilities On March 13, 2019 , Agilent entered into a credit agreement with a group of financial institutions which provides for a $1 billion five -year unsecured credit facility that will expire on March 13, 2024 . The credit facility replaces the existing credit facility which was terminated on the closing date of the new facility. As of April 30, 2019 , the company had no borrowings outstanding under the credit facility. We were in compliance with the covenants for all the credit facilities during the three and six months ended April 30, 2019 .

LONG-TERM DEBT (Notes)

LONG-TERM DEBT (Notes)	6 Months Ended
	Apr. 30, 2019
Debt Disclosure [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT Senior Notes The following table summarizes the company’s long-term senior notes and the related interest rate swaps: April 30, 2019 October 31, 2018 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2020 Senior Notes 499 5 504 499 7 506 2022 Senior Notes 399 — 399 399 — 399 2023 Senior Notes 597 — 597 597 — 597 2026 Senior Notes 298 — 298 297 — 297 Total $ 1,793 $ 5 $ 1,798 $ 1,792 $ 7 $ 1,799 All outstanding notes listed above are unsecured and rank equally in right of payment with all of Agilent’s other senior unsecured indebtedness. There have been no changes to the principal, maturity, interest rates and interest payment terms of the Agilent senior notes, detailed in the table above, in the six months ended April 30, 2019 as compared to the senior notes described in our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 . All interest rate swap contracts have been terminated and amounts to be amortized over the remaining life of the senior notes as of April 30, 2019 and October 31, 2018 are detailed above.

STOCKHOLDERS' EQUITY (Notes)

STOCKHOLDERS' EQUITY (Notes)	6 Months Ended
	Apr. 30, 2019
Stockholders' Equity Note [Abstract]
STOCKHOLDERS EQUITY	STOCKHOLDERS' EQUITY Stock Repurchase Program On November 19, 2018 we announced that our board of directors had approved a new share repurchase program (the "2019 repurchase program") designed, among other things, to reduce or eliminate dilution resulting from issuance of stock under the company's employee equity incentive programs. The 2019 repurchase program authorizes the purchase of up to $1.75 billion of our common stock at the company's discretion and has no fixed termination date. The 2019 repurchase program does not require the company to acquire a specific number of shares and may be suspended, amended or discontinued at any time. During the three and six months ended April 30, 2019 , we repurchased approximately 638,000 shares for $50 million and 1.766 million shares for $125 million , respectively, under this authorization. During the three and six months ended April 30, 2019 , we retired approximately 629,000 shares for $49 million and 1.757 million shares for $124 million , respectively. The remaining 9,000 treasury shares were retired on May 1, 2019. As of April 30, 2019 , we had remaining authorization to repurchase up to $1.625 billion of our common stock under this program. On May 28, 2015, we announced that our board of directors had approved a new share repurchase program (the "2015 repurchase program"). The 2015 repurchase program authorized the purchase of up to $1.14 billion of our common stock at the company's discretion through and including November 1, 2018. The 2015 repurchase program did not require the company to acquire a specific number of shares and could have been suspended or discontinued at any time. During the three and six months ended April 30, 2018 , we repurchased 674,000 shares for $46 million and 1.3 million shares for $93 million , respectively, under this authorization. During the three and six months ended April 30, 2018 , we retired approximately 711,000 treasury shares for $49 million and 1.3 million treasury shares for $93 million , respectively. On November 1, 2018, the remaining authorization of $188 million under this repurchase program expired. Cash Dividends on Shares of Common Stock During the three and six months ended April 30, 2019 , we paid cash dividends of $0.164 per common share or $52 million and $0.328 per common share or $104 million , respectively, on the company's common stock. During the three and six months ended April 30, 2018 , we paid cash dividends of $0.149 per common share or $48 million and $0.298 per common share or $96 million on the company's common stock. On May 22, 2019 , our board of directors declared a quarterly dividend of $0.164 per share of common stock or approximately $53 million which will be paid on July 24, 2019 to all shareholders of record at close of business on July 2, 2019 . The timing and amounts of any future dividends are subject to determination and approval by our board of directors. Accumulated Other Comprehensive Income (Loss) Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended April 30, 2019 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of January 31, 2019 $ (176 ) $ 135 $ (338 ) $ (2 ) $ (381 ) Other comprehensive income (loss) before reclassifications (25 ) — (2 ) 4 (23 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (2 ) 10 — 8 Tax (expense) benefit — 1 (2 ) (1 ) (2 ) Other comprehensive income (loss) (25 ) (1 ) 6 3 (17 ) As of April 30, 2019 $ (201 ) $ 134 $ (332 ) $ 1 $ (398 ) Six Months Ended April 30, 2019 As of October 31, 2018 $ (214 ) $ 134 $ (335 ) $ 7 $ (408 ) Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss) — 3 (9 ) (1 ) (7 ) (214 ) 137 (344 ) 6 (415 ) Other comprehensive income (loss) before reclassifications 4 — (2 ) (2 ) — Amounts reclassified out of accumulated other comprehensive income (loss) — (4 ) 20 (5 ) 11 Tax (expense) benefit 9 1 (6 ) 2 6 Other comprehensive income (loss) 13 (3 ) 12 (5 ) 17 As of April 30, 2019 $ (201 ) $ 134 $ (332 ) $ 1 $ (398 ) Reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended April 30, 2019 and 2018 were as follows (in millions): Details about accumulated other comprehensive income (loss) components Amounts Reclassified from other comprehensive income (loss) Affected line item in statement of operations Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 Unrealized gain (loss) on derivatives $ — $ (5 ) $ 5 $ (5 ) Cost of products — (5 ) 5 (5 ) Total before income tax — 2 (1 ) 2 (Provision) benefit for income tax — (3 ) 4 (3 ) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (10 ) (10 ) (20 ) (19 ) Prior service benefit 2 2 4 4 (8 ) (8 ) (16 ) (15 ) Total before income tax 1 3 5 4 Benefit for income tax (7 ) (5 ) (11 ) (11 ) Total net of income tax Total reclassifications for the period $ (7 ) $ (8 ) $ (7 ) $ (14 ) Amounts in parentheses indicate reductions to income and increases to other comprehensive income (loss). Reclassifications out of accumulated other comprehensive income (loss) of prior service benefit and actuarial net loss in respect of retirement plans and post retirement pension plans are included in the computation of net periodic cost together with curtailments and settlements (see Note 11, "Retirement Plans and Post Retirement Pension Plans").

SEGMENT INFORMATION (Notes)

SEGMENT INFORMATION (Notes)	6 Months Ended
	Apr. 30, 2019
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Description of segments. We are a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Agilent has three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business each of which comprises a reportable segment. The three operating segments were determined based primarily on how the chief operating decision maker views and evaluates our operations. Operating results are regularly reviewed by the chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance. Other factors, including market separation and customer specific applications, go-to-market channels, products and services and manufacturing are considered in determining the formation of these operating segments. In 2019, we adopted new guidance related to the presentation of the net periodic pension and postretirement benefit cost. See Note 2, "New Accounting Pronouncements" for more information. As a result, we have recast our historical segment results to conform to this new presentation required under this guidance. Also, in the third quarter of 2018, we re-organized our operating segments and moved the microfluidics business from our life sciences and applied markets operating segment to our diagnostics and genomics operating segment. Following this re-organization, we continue to have three business segments comprised of the life sciences and applied markets business, diagnostics and genomics business and the Agilent CrossLab business. All historical financial segment information for both the life sciences and applied markets segment and the diagnostics and genomics segment has been recast to reflect this reorganization in our financial statements. A description of our three reportable segments is as follows: Our life sciences and applied markets business provides application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products, as well as enable customers in the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. Key product categories include: liquid chromatography ("LC") systems and components; liquid chromatography mass spectrometry ("LCMS") systems; gas chromatography ("GC") systems and components; gas chromatography mass spectrometry ("GCMS") systems; inductively coupled plasma mass spectrometry ("ICP-MS") instruments; atomic absorption ("AA") instruments; microwave plasma-atomic emission spectrometry (“MP-AES”) instruments; inductively coupled plasma optical emission spectrometry ("ICP-OES") instruments; Raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; laboratory software for sample tracking; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps and measurement technologies. Our diagnostics and genomics business is comprised of six areas of activity providing active pharmaceutical ingredients ("APIs") for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables, which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. First, our genomics business includes arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, as well as next generation sequencing ("NGS") target enrichment and genetic data management and interpretation support software. This business also includes solutions that enable clinical labs to identify DNA variants associated with genetic disease and help direct cancer therapy. Second, our nucleic acid solutions business provides equipment and expertise focused on production of synthesized oligonucleotides under pharmaceutical good manufacturing practices ("GMP") conditions for use as API in an emerging class of drugs that utilize nucleic acid molecules for disease therapy. Third, our pathology solutions business is focused on product offerings for cancer diagnostics and anatomic pathology workflows. The broad portfolio of offerings includes immunohistochemistry (“IHC”), in situ hybridization (“ISH”), hematoxylin and eosin (“H&E”) staining and special staining. Fourth, we also collaborate with a number of major pharmaceutical companies to develop new potential pharmacodiagnostics, also known as companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. Fifth, the reagent partnership business is a provider of reagents used for turbidimetry and flow cytometry. Finally, our biomolecular analysis business provides complete workflow solutions, including instruments, consumables and software, for quality control analysis of nucleic acid samples. Samples are analyzed using quantitative and qualitative techniques to ensure accuracy in further genomics analysis techniques utilized in clinical and life science research applications. The Agilent CrossLab business spans the entire lab with its extensive consumables and services portfolio, which is designed to improve customer outcomes. Most of the portfolio is vendor neutral, meaning Agilent can serve and supply customers regardless of their instrument purchase choices. Solutions range from chemistries and supplies to services and software helping to connect the entire lab. Key product categories in consumables include GC and LC columns, sample preparation products, custom chemistries, and a large selection of laboratory instrument supplies. Services include startup, operational, training and compliance support, software as a service, as well as asset management and consultative services that help increase customer productivity. Custom service and consumable bundles are tailored to meet the specific application needs of various industries and to keep instruments fully operational and compliant with the respective industry requirements. A significant portion of the segments' expenses arise from shared services and infrastructure that we have historically provided to the segments in order to realize economies of scale and to efficiently use resources. These expenses, collectively called corporate charges, include legal, accounting, tax, real estate, insurance services, information technology services, treasury, order administration, other corporate infrastructure expenses and costs of centralized research and development. Charges are allocated to the segments, and the allocations have been determined on a basis that we consider to be a reasonable reflection of the utilization of services provided to or benefits received by the segments. In addition, we do not allocate amortization and impairment of acquisition-related intangible assets, transformational initiatives expenses, acquisition and integration costs, special compliance costs, some nucleic acid solutions division ("NASD") site costs and certain other charges to the operating margin for each segment because management does not include this information in its measurement of the performance of the operating segments. Transformational initiatives include expenses associated with targeted cost reduction activities such as manufacturing transfers, site consolidations, legal entity and other business reorganizations and in-sourcing or outsourcing of activities. The following tables reflect the results of our reportable segments under our management reporting system. The performance of each segment is measured based on several metrics, including segment income from operations. These results are used, in part, by the chief operating decision maker in evaluating the performance of, and in allocating resources to, each of the segments. The profitability of each of the segments is measured after excluding transformational initiatives, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Net Revenue: Life Sciences and Applied Markets $ 529 $ 537 $ 1,136 $ 1,133 Diagnostics and Genomics 254 243 489 450 Agilent CrossLab 455 426 897 834 Total net revenue $ 1,238 $ 1,206 $ 2,522 $ 2,417 Segment Income From Operations: Life Sciences and Applied Markets $ 107 $ 113 $ 266 $ 267 Diagnostics and Genomics 49 48 82 72 Agilent CrossLab 115 96 220 183 Total segment income from operations $ 271 $ 257 $ 568 $ 522 The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Total reportable segments’ income from operations $ 271 $ 257 $ 568 $ 522 Transformational initiatives (9 ) (5 ) (14 ) (9 ) Amortization of intangible assets related to business combinations (26 ) (25 ) (54 ) (50 ) Acquisition and integration costs (10 ) (4 ) (20 ) (7 ) Business exit and divestiture costs — (8 ) — (8 ) NASD site costs (4 ) (2 ) (6 ) (4 ) Special compliance costs (1 ) (1 ) (1 ) (2 ) Other (5 ) (2 ) (7 ) (3 ) Interest income 10 10 20 19 Interest expense (17 ) (19 ) (35 ) (39 ) Other income (expense), net 9 26 15 41 Income before taxes, as reported $ 218 $ 227 $ 466 $ 460 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. April 30, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 2,023 $ 1,744 Diagnostics and Genomics 2,617 2,679 Agilent CrossLab 1,307 1,267 Total segment assets $ 5,947 $ 5,690

OVERVIEW, BASIS OF PRESENTATI_2

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Overview and Basis of Presentation	Overview. Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied chemical markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Our fiscal year-end is October 31, and our fiscal quarters end on January 31, April 30 and July 31. Unless otherwise stated, these dates refer to our fiscal year and fiscal quarters. Basis of Presentation . We have prepared the accompanying financial data for the three and six months ended April 30, 2019 and 2018 pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles (“GAAP”) in the U.S. have been condensed or omitted pursuant to such rules and regulations. The October 31, 2018 condensed balance sheet data was derived from audited financial statements but does not include all the disclosures required in audited financial statements by U.S. GAAP. The accompanying financial data and information should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 . In the opinion of management, the accompanying condensed consolidated financial statements contain all normal and recurring adjustments necessary for a fair statement of our condensed consolidated balance sheet as of April 30, 2019 and October 31, 2018 , condensed consolidated statement of comprehensive income (loss) for the three and six months ended April 30, 2019 and 2018 , condensed consolidated statement of operations for the three and six months ended April 30, 2019 and 2018 , condensed consolidated statement of cash flows for the six months ended April 30, 2019 and 2018 and condensed consolidated statement of equity for the three and six months ended April 30, 2019 and 2018 .
Use of Estimates	Use of Estimates. The preparation of condensed consolidated financial statements in accordance with GAAP in the U.S. requires management to make estimates and assumptions that affect the amounts reported in our condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and various other assumptions believed to be reasonable. Although these estimates are based on management’s best knowledge of current events and actions that may impact the company in the future, actual results may be different from the estimates. Our critical accounting policies are those that affect our financial statements materially and involve difficult, subjective or complex judgments by management. Those policies are revenue recognition, inventory valuation, share-based compensation, retirement and post-retirement benefit plan assumptions, goodwill and purchased intangible assets and accounting for income taxes.
Fair Value of Financial Instruments	Fair Value of Financial Instruments. The carrying values of certain of our financial instruments including cash and cash equivalents, accounts receivable, accounts payable, accrued compensation and other accrued liabilities approximate fair value because of their short maturities. The fair value of long-term equity investments which are readily determinable, and which are not accounted under the equity method are reported at fair value using quoted market prices for those securities when available with gains and losses included in net income. The fair value of long-term equity investments which are not readily determinable, and which are not accounted under the equity method are reported at cost with adjustments for observable changes in prices or impairments included in net income. The fair value of our senior notes, calculated from quoted prices which are primarily Level 1 inputs under the accounting guidance fair value hierarchy, exceeds the carrying value by approximately $27 million and is lower than the carrying value by approximately $15 million as of April 30, 2019 and October 31, 2018 , respectively. The change in the fair value over carrying value in the six months ended April 30, 2019 is primarily due to fluctuations in market interest rates. The fair value of foreign currency contracts used for hedging purposes is estimated internally by using inputs tied to active markets. These inputs, for example, interest rate yield curves, foreign exchange rates, and forward and spot prices for currencies are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. See also Note 9, "Fair Value Measurements" for additional information on the fair value of financial instruments.
Revenue Recognition	Revenue Recognition . We enter into agreements to sell products (hardware and/or software), services and other arrangements (multiple element arrangements) that include combinations of products and services. We derive revenue primarily from the sale of analytical and diagnostics products and services. A performance obligation is a promise in a contract to transfer a distinct product or service to a customer and is the unit of account under Accounting Standard Codification Topic 606, Revenue from Contracts with Customers (“ASC 606’’). See also Note 2, "New Accounting Pronouncements" and Note 3, "Revenue" for additional information on revenue recognition. Revenue is recognized when control of the promised products or services is transferred to our customers and the performance obligation is fulfilled in an amount that reflects the consideration that we expect to be entitled to in exchange for those products or services, the transaction price. For equipment, consumables, and most software licenses sold by us, control transfers to the customer at a point in time. We use present right to payment, legal title, physical possession of the asset, and risks and rewards of ownership as indicators to determine the transfer of control to the customer. Where acceptance is not a formality, the customer must have documented their acceptance of the product or service. For products that include installation, if the installation meets the criteria to be considered a separate performance obligation, product revenue is recognized when control has passed to the customer, and recognition of installation revenue occurs once completed. Product revenue, including sales to resellers and distributors is reduced for provisions for warranties, returns, and other adjustments in the period the related sales are recorded. Revenue from services includes extended warranty, customer and software support including: Software as a Service, post contract support, consulting including companion diagnostics, and training and education. Instrument service contracts and software maintenance contracts are typically annual contracts, which are billed at the beginning of the contract or maintenance period. These contracts are recognized on a straight-line basis to revenue over the service period, as a time-based measure of progress best reflects our performance in satisfying this obligation. There are no deferred costs associated with the service contract, as the cost of the service is recorded when the service is performed. Service calls are recognized to revenue at the time a service is performed. We have sales from standalone software. These arrangements typically include software licenses and maintenance contracts, both of which we have determined are distinct performance obligations. We determine the amount of the transaction price to allocate to the license and maintenance contract based on the relative standalone selling price of each performance obligation. Software license revenue is recognized at the point in time when control has been transferred to the customer. The revenue allocated to the software maintenance contract is recognized on a straight-line basis over the maintenance period, which is the contractual term of the contract, as a time-based measure of progress best reflects our performance in satisfying this obligation. Unspecified rights to software upgrades are typically sold as part of the maintenance contract on a when-and-if-available basis. Our multiple-element arrangements are generally comprised of a combination of instruments, installation or other start-up services, and/or software, and/or support or services. Hardware and software elements are typically delivered at the same time and revenue is recognized when control passes to the customer. Service revenue is deferred and recognized over the contractual period or as services are rendered and accepted by the customer. Our arrangements generally do not include any provisions for cancellation, termination, or refunds that would significantly impact recognized revenue. For contracts with multiple performance obligations, we allocate the consideration to which we expect to be entitled to each performance obligation based on relative standalone selling prices and recognize the related revenue when or as control of each individual performance obligation is transferred to customers. We estimate the standalone selling price by calculating the average historical selling price of our products and services per country for each performance obligation. Stand-alone selling prices are determined at contract inception for each distinct good or service in the contract and then we allocate the transaction price in proportion to those standalone selling prices by performance obligations. Certain of our revenue relate to lease arrangements. Standalone lease arrangements are outside the scope of ASC 606 and are therefore accounted for in accordance with ASC 840, Leases. Each of these contracts is evaluated as a lease arrangement, either as an operating lease or a sales-type capital lease using the current lease classification guidance.

NEW ACCOUNTING PRONOUNCEMENTS_2

NEW ACCOUNTING PRONOUNCEMENTS (Tables)	6 Months Ended
	Apr. 30, 2019
Accounting Policies [Abstract]
Summary of New Accounting Pronouncements	The following table summarizes the impacts of recently adopted accounting pronouncements on our condensed consolidated balance sheet as of November 1, 2018: October 31, Impact of Adopting New November 1, As Reported Revenue Recognition Guidance Tax Effects on Items in AOCI Guidance Intra-Entity Tax Guidance Investments Valuation Guidance As Adopted (in millions) ASSETS Current assets: Cash and cash equivalents $ 2,247 $ — $ — $ — $ — $ 2,247 Accounts receivable, net 776 24 — — — 800 Inventory 638 (10 ) — — — 628 Other current assets 187 3 — — — 190 Total current assets 3,848 17 — — — 3,865 Property, plant and equipment, net 822 — — — — 822 Goodwill 2,973 — — — — 2,973 Other intangible assets, net 491 — — — — 491 Long-term investments 68 — — — 7 75 Other assets 339 (3 ) — (2 ) (2 ) 332 Total assets $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 340 $ — $ — $ — $ — $ 340 Employee compensation and benefits 304 — — — — 304 Deferred revenue 324 (11 ) — — — 313 Other accrued liabilities 203 — — — — 203 Total current liabilities 1,171 (11 ) — — — 1,160 Long-term debt 1,799 — — — — 1,799 Retirement and post-retirement benefits 239 — — — — 239 Other long-term liabilities 761 2 — — — 763 Total liabilities 3,970 (9 ) — — — 3,961 Total equity: Stockholders’ equity: Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding — — — — — — Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018 issued 3 — — — — 3 Additional paid-in-capital 5,308 — — — — 5,308 Accumulated deficit (336 ) 23 7 (2 ) 5 (303 ) Accumulated other comprehensive loss (408 ) — (7 ) — — (415 ) Total stockholders' equity 4,567 23 — (2 ) 5 4,593 Non-controlling interest 4 — — — — 4 Total equity 4,571 23 — (2 ) 5 4,597 Total liabilities and equity $ 8,541 $ 14 $ — $ (2 ) $ 5 $ 8,558 As of November 1, 2018, we adopted new accounting guidance which requires amounts generally described as restricted cash and restricted cash equivalents to be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. A reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheet follows: April 30, October 31 2019 2018 (in millions) Cash and cash equivalents $ 2,155 $ 2,247 Restricted cash included in other assets 6 7 Total cash, cash equivalents and restricted cash $ 2,161 $ 2,254

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Apr. 30, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	The following table presents the company’s total revenue and segment revenue disaggregated by geographical region: Three Months Ended April 30, 2019 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Revenue by Region Americas $ 145 $ 120 $ 168 $ 433 Europe 125 97 132 354 Asia Pacific 259 37 155 451 Total $ 529 $ 254 $ 455 $ 1,238 Six Months Ended April 30, 2019 Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Revenue by Region Americas $ 313 $ 229 $ 324 $ 866 Europe 289 188 260 737 Asia Pacific 534 72 313 919 Total $ 1,136 $ 489 $ 897 $ 2,522
Contract Liabilities and Changes in Balances	The following table provides information about contract liabilities (deferred revenue) and the significant changes in the balances during the six months ended April 30, 2019 : Contract Liabilities (in millions) Ending balance as of October 31, 2018 $ 367 Impact of adoption of new revenue recognition guidance (11 ) Net revenue deferred in the period 224 Revenue recognized that was included in the contract liability balance at the beginning of the period (191 ) Change in deferrals from customer cash advances, net of revenue recognized 2 Contract liabilities acquired in business combinations 2 Currency translation and other adjustments 1 Ending balance as of April 30, 2019 $ 394

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	6 Months Ended
	Apr. 30, 2019
Share-based Compensation [Abstract]
Allocated share-based compensation expense disclosure	The impact on our results for share-based compensation was as follows: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Cost of products and services $ 4 $ 3 $ 9 $ 10 Research and development 2 1 4 4 Selling, general and administrative 10 8 27 29 Total share-based compensation expense $ 16 $ 12 $ 40 $ 43
Assumptions used to estimate fair value for LTPP	The following assumptions were used to estimate the fair value of awards granted. Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 LTPP: Volatility of Agilent shares 22% 21% 22% 21% Volatility of selected peer-company shares 15%-66% 14%-66% 15%-66% 14%-66% Pair-wise correlation with selected peers 30% 32% 30% 32% Post-vest holding restriction discount for all executive awards 5.0% 4.8% 5.0% 4.8%

NET INCOME PER SHARE (Tables)

NET INCOME PER SHARE (Tables)	6 Months Ended
	Apr. 30, 2019
Earnings Per Share [Abstract]
Reconciliation of the numerators and denominators of the basic and diluted net income per share	The following is a reconciliation of the numerator and denominator of the basic and diluted net income per share computations for the periods presented below: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Numerator: Net income (loss) $ 182 $ 205 $ 686 $ (115 ) Denominator: Basic weighted-average shares 317 322 318 323 Potential common shares— stock options and other employee stock plans 4 4 4 — Diluted weighted-average shares 321 326 322 323

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Apr. 30, 2019
Inventory, Net [Abstract]
INVENTORY	INVENTORY April 30, October 31, (in millions) Finished goods $ 401 $ 386 Purchased parts and fabricated assemblies 256 252 Inventory $ 657 $ 638

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	6 Months Ended
	Apr. 30, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill balances and movements for each reportable segments during the period	The following table presents goodwill balances and the movements for each of our reportable segments during the six months ended April 30, 2019 : Life Sciences and Applied Markets Diagnostics and Genomics Agilent CrossLab Total (in millions) Goodwill as of October 31, 2018 $ 803 $ 1,607 $ 563 $ 2,973 Foreign currency translation impact — (2 ) (1 ) (3 ) Goodwill arising from acquisitions and adjustments 153 (11 ) — 142 Goodwill as of April 30, 2019 $ 956 $ 1,594 $ 562 $ 3,112
Components of other intangibles during the period	The components of other intangible assets as of April 30, 2019 and October 31, 2018 are shown in the table below: Purchased Other Intangible Assets Gross Carrying Amount Accumulated Amortization and Impairments Net Book Value (in millions) As of October 31, 2018 Purchased technology $ 947 $ 683 $ 264 Trademark/Tradename 151 88 63 Customer relationships 107 63 44 Third-party technology and licenses 28 19 9 Total amortizable intangible assets 1,233 853 380 In-Process R&D 111 — 111 Total $ 1,344 $ 853 $ 491 As of April 30, 2019 Purchased technology $ 1,026 $ 720 $ 306 Trademark/Tradename 153 95 58 Customer relationships 127 71 56 Third-party technology and licenses 28 21 7 Total amortizable intangible assets 1,334 907 427 In-Process R&D 111 — 111 Total $ 1,445 $ 907 $ 538
Schedule of estimated future amortization expense of finite-lived intangible assets	Future amortization expense related to existing finite-lived purchased intangible assets for the remainder of fiscal year 2019 and for each of the five succeeding fiscal years and thereafter is estimated below: Estimated future amortization expense: (in millions) Remainder of 2019 $ 53 2020 $ 94 2021 $ 81 2022 $ 65 2023 $ 55 2024 $ 46 Thereafter $ 33

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	6 Months Ended
	Apr. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Assets And Liabilities Measured On Recurring Basis	Financial assets and liabilities measured at fair value on a recurring basis as of April 30, 2019 were as follows: Fair Value Measurement at April 30, 2019 Using April 30, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,229 $ 1,229 $ — $ — Derivative instruments (foreign exchange contracts) 6 — 6 — Long-term Trading securities 31 31 — — Other investments 24 — 24 — Total assets measured at fair value $ 1,290 $ 1,260 $ 30 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 2 $ — $ 2 $ — Long-term Deferred compensation liability 31 — 31 — Total liabilities measured at fair value $ 33 $ — $ 33 $ — Financial assets and liabilities measured at fair value on a recurring basis as of October 31, 2018 were as follows: Fair Value Measurement at October 31, 2018 Using October 31, Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) (in millions) Assets: Short-term Cash equivalents (money market funds) $ 1,355 $ 1,355 $ — $ — Derivative instruments (foreign exchange contracts) 16 — 16 — Long-term Trading securities 30 30 — — Total assets measured at fair value $ 1,401 $ 1,385 $ 16 $ — Liabilities: Short-term Derivative instruments (foreign exchange contracts) $ 5 $ — $ 5 $ — Long-term Deferred compensation liability 30 — 30 — Total liabilities measured at fair value $ 35 $ — $ 35 $ —

DERIVATIVES (Tables)

DERIVATIVES (Tables)	6 Months Ended
	Apr. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Aggregated notional amounts by currency and designation	The aggregated notional amounts by currency and designation as of April 30, 2019 were as follows: Derivatives Designated as Cash Flow Hedges Derivatives Not Designated as Hedging Instruments Forward Contracts USD Forward Contracts USD Currency Buy/(Sell) Buy/(Sell) (in millions) Euro $ (57 ) $ 33 British Pound (56 ) 7 Canadian Dollar (30 ) (4 ) Australian Dollar 5 4 Malaysian Ringgit — (2 ) Japanese Yen (97 ) 14 Danish Krone — (4 ) Korean Won (50 ) (31 ) Singapore Dollar 17 (5 ) Swiss Franc — (7 ) Chinese Yuan Renminbi (57 ) (33 ) Polish Zloty — (3 ) Swedish Krona — (9 ) Other — (9 ) Totals $ (325 ) $ (49 )
Gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet	Derivative instruments are subject to master netting arrangements and are disclosed gross in the balance sheet in accordance with the authoritative guidance. The gross fair values and balance sheet location of derivative instruments held in the consolidated balance sheet as of April 30, 2019 and October 31, 2018 were as follows: Fair Values of Derivative Instruments Asset Derivatives Liability Derivatives Fair Value Fair Value Balance Sheet Location April 30, October 31, Balance Sheet Location April 30, October 31, (in millions) Derivatives designated as hedging instruments: Cash flow hedges Foreign exchange contracts Other current assets $ 4 $ 11 Other accrued liabilities $ 1 $ 1 Derivatives not designated as hedging instruments: Foreign exchange contracts Other current assets $ 2 $ 5 Other accrued liabilities $ 1 $ 4 Total derivatives $ 6 $ 16 $ 2 $ 5
Effect of derivative instruments for foreign exchange contracts in the consolidated statement of operations	The effect of derivative instruments for foreign exchange contracts designated as hedging instruments and not designated as hedging instruments in our consolidated statement of operations were as follows: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Derivatives designated as hedging instruments: Cash Flow Hedges Foreign exchange contracts: Gain (loss) recognized in accumulated other comprehensive income (loss) $ 4 $ 5 $ (2 ) $ (5 ) Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales $ — $ (5 ) $ 5 $ (5 ) Gain on time value of forward contracts recorded in cost of sales $ 1 $ — $ 2 $ — Derivatives not designated as hedging instruments: Gain (loss) recognized in other income (expense) $ 1 $ (5 ) $ (2 ) $ 1

RETIREMENT PLANS AND POST RET_2

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Tables)	6 Months Ended
	Apr. 30, 2019
Defined Benefit Plan [Abstract]
Schedule of net pension and post-retirement benefit costs	Components of net periodic costs. For the three and six months ended April 30, 2019 and 2018 , our net pension and post retirement benefit costs were comprised of the following: Three Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement Benefit Plans 2019 2018 2019 2018 2019 2018 (in millions) Service cost—benefits earned during the period $ — $ — $ 4 $ 4 $ — $ — Interest cost on benefit obligation 5 4 3 3 1 1 Expected return on plan assets (7 ) (7 ) (11 ) (12 ) (1 ) (2 ) Amortization: Actuarial losses — — 9 8 1 2 Prior service credits — — — — (2 ) (2 ) Total net plan costs $ (2 ) $ (3 ) $ 5 $ 3 $ (1 ) $ (1 ) Six Months Ended April 30, U.S. Non-U.S. U.S. Post Retirement 2019 2018 2019 2018 2019 2018 (in millions) Service cost—benefits earned during the period $ — $ — $ 10 $ 10 $ — $ — Interest cost on benefit obligation 10 8 6 6 1 2 Expected return on plan assets (14 ) (14 ) (22 ) (23 ) (2 ) (4 ) Amortization: Actuarial losses — — 18 15 2 4 Prior service credits — — — — (4 ) (4 ) Total net plan costs $ (4 ) $ (6 ) $ 12 $ 8 $ (3 ) $ (2 ) Settlements gains $ — $ — $ — $ (5 ) $ — $ —

WARRANTIES AND CONTINGENCIES (T

WARRANTIES AND CONTINGENCIES (Tables)	6 Months Ended
	Apr. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Standard warranty	A summary of the standard warranty accrual activity is shown in the table below: Six Months Ended April 30, 2019 2018 (in millions) Beginning balance as of November 1, $ 35 $ 34 Accruals for warranties including change in estimate 27 25 Settlements made during the period (30 ) (26 ) Ending balance as of April 30, $ 32 $ 33 Accruals for warranties due within one year $ 32 $ 33

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	6 Months Ended
	Apr. 30, 2019
Debt Disclosure [Abstract]
Schedule of Senior Notes and Related Interest Rate Swaps	The following table summarizes the company’s long-term senior notes and the related interest rate swaps: April 30, 2019 October 31, 2018 Amortized Principal Swap Total Amortized Principal Swap Total (in millions) 2020 Senior Notes 499 5 504 499 7 506 2022 Senior Notes 399 — 399 399 — 399 2023 Senior Notes 597 — 597 597 — 597 2026 Senior Notes 298 — 298 297 — 297 Total $ 1,793 $ 5 $ 1,798 $ 1,792 $ 7 $ 1,799

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Apr. 30, 2019
Schedule of Accumulated Other Comprehensive Income (Loss)	Changes in accumulated other comprehensive income (loss) by component and related tax effects were as follows (in millions): Net defined benefit pension cost and post retirement plan costs Three Months Ended April 30, 2019 Foreign currency translation Prior service credits Actuarial Losses Unrealized gains (losses) on derivatives Total (in millions) As of January 31, 2019 $ (176 ) $ 135 $ (338 ) $ (2 ) $ (381 ) Other comprehensive income (loss) before reclassifications (25 ) — (2 ) 4 (23 ) Amounts reclassified out of accumulated other comprehensive income (loss) — (2 ) 10 — 8 Tax (expense) benefit — 1 (2 ) (1 ) (2 ) Other comprehensive income (loss) (25 ) (1 ) 6 3 (17 ) As of April 30, 2019 $ (201 ) $ 134 $ (332 ) $ 1 $ (398 ) Six Months Ended April 30, 2019 As of October 31, 2018 $ (214 ) $ 134 $ (335 ) $ 7 $ (408 ) Impact of adoption of new guidance on tax effects in accumulated other comprehensive income (loss) — 3 (9 ) (1 ) (7 ) (214 ) 137 (344 ) 6 (415 ) Other comprehensive income (loss) before reclassifications 4 — (2 ) (2 ) — Amounts reclassified out of accumulated other comprehensive income (loss) — (4 ) 20 (5 ) 11 Tax (expense) benefit 9 1 (6 ) 2 6 Other comprehensive income (loss) 13 (3 ) 12 (5 ) 17 As of April 30, 2019 $ (201 ) $ 134 $ (332 ) $ 1 $ (398 )
Reclassification out of Accumulated Other Comprehensive Income	Reclassifications out of accumulated other comprehensive income (loss) for the three and six months ended April 30, 2019 and 2018 were as follows (in millions): Details about accumulated other comprehensive income (loss) components Amounts Reclassified from other comprehensive income (loss) Affected line item in statement of operations Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 Unrealized gain (loss) on derivatives $ — $ (5 ) $ 5 $ (5 ) Cost of products — (5 ) 5 (5 ) Total before income tax — 2 (1 ) 2 (Provision) benefit for income tax — (3 ) 4 (3 ) Total net of income tax Net defined benefit pension cost and post retirement plan costs: Actuarial net loss (10 ) (10 ) (20 ) (19 ) Prior service benefit 2 2 4 4 (8 ) (8 ) (16 ) (15 ) Total before income tax 1 3 5 4 Benefit for income tax (7 ) (5 ) (11 ) (11 ) Total net of income tax Total reclassifications for the period $ (7 ) $ (8 ) $ (7 ) $ (14 )

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Apr. 30, 2019
Segment Reporting [Abstract]
Segment Profitability and Segment Assets	The profitability of each of the segments is measured after excluding transformational initiatives, investment gains and losses, interest income, interest expense, acquisition and integration costs, non-cash amortization and other items as noted in the reconciliations below: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Net Revenue: Life Sciences and Applied Markets $ 529 $ 537 $ 1,136 $ 1,133 Diagnostics and Genomics 254 243 489 450 Agilent CrossLab 455 426 897 834 Total net revenue $ 1,238 $ 1,206 $ 2,522 $ 2,417 Segment Income From Operations: Life Sciences and Applied Markets $ 107 $ 113 $ 266 $ 267 Diagnostics and Genomics 49 48 82 72 Agilent CrossLab 115 96 220 183 Total segment income from operations $ 271 $ 257 $ 568 $ 522 The following table reflects segment assets under our management reporting system. Segment assets include allocations of corporate assets, goodwill, net other intangibles and other assets. Unallocated assets primarily consist of cash, cash equivalents, the valuation allowance relating to deferred tax assets and other assets. April 30, October 31, (in millions) Segment Assets: Life Sciences and Applied Markets $ 2,023 $ 1,744 Diagnostics and Genomics 2,617 2,679 Agilent CrossLab 1,307 1,267 Total segment assets $ 5,947 $ 5,690
Reconciliation of segment results to total enterprise results	The following table reconciles reportable segments’ income from operations to Agilent’s total enterprise income before taxes: Three Months Ended Six Months Ended April 30, April 30, 2019 2018 2019 2018 (in millions) Total reportable segments’ income from operations $ 271 $ 257 $ 568 $ 522 Transformational initiatives (9 ) (5 ) (14 ) (9 ) Amortization of intangible assets related to business combinations (26 ) (25 ) (54 ) (50 ) Acquisition and integration costs (10 ) (4 ) (20 ) (7 ) Business exit and divestiture costs — (8 ) — (8 ) NASD site costs (4 ) (2 ) (6 ) (4 ) Special compliance costs (1 ) (1 ) (1 ) (2 ) Other (5 ) (2 ) (7 ) (3 ) Interest income 10 10 20 19 Interest expense (17 ) (19 ) (35 ) (39 ) Other income (expense), net 9 26 15 41 Income before taxes, as reported $ 218 $ 227 $ 466 $ 460

OVERVIEW, BASIS OF PRESENTATI_3

OVERVIEW, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Fair Value of Financial Instruments
Fair value of senior notes in excess of carrying value	$ 27
Fair value of senior notes lower than carrying value		$ 15

NEW ACCOUNTING PRONOUNCEMENTS-

NEW ACCOUNTING PRONOUNCEMENTS- Initial Adoption (Details) - USD ($) $ in Millions	Apr. 30, 2019	Jan. 31, 2019	Nov. 01, 2018	Oct. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Oct. 31, 2017
Current assets:
Cash and cash equivalents	$ 2,155		$ 2,247	$ 2,247
Accounts receivable, net	819		800	776
Inventory	657		628	638
Other current assets	181		190	187
Total current assets	3,812		3,865	3,848
Property, plant and equipment, net	827		822	822
Goodwill	3,112		2,973	2,973
Other intangible assets, net	538		491	491
Long-term investments	96		75	68
Other assets	637		332	339
Total assets	9,022		8,558	8,541
Current liabilities:
Accounts payable	314		340	340
Employee compensation and benefits	292		304	304
Deferred revenue	347		313	324
Other accrued liabilities	165		203	203
Total current liabilities	1,118		1,160	1,171
Long-term debt	1,798		1,799	1,799
Retirement and post-retirement benefits	229		239	239
Other long-term liabilities	752		763	761
Total liabilities	3,897		3,961	3,970
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding	0		0	0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018, issued	3		3	3
Additional paid-in-capital	5,343		5,308	5,308
Retained earnings (accumulated deficit)	178		(303)	(336)
Accumulated other comprehensive loss	(398)	$ (381)	(415)	(408)
Total stockholder's equity	5,125		4,593	4,567
Non-controlling interest	0		4	4
Total equity	5,125	$ 5,036	4,597	4,571	$ 4,617	$ 4,526	$ 4,835
Total liabilities and equity	$ 9,022		8,558	$ 8,541
Impact of Adopting New Revenue Guidance
Current assets:
Cash and cash equivalents			0
Accounts receivable, net			24
Inventory			(10)
Other current assets			3
Total current assets			17
Property, plant and equipment, net			0
Goodwill			0
Other intangible assets, net			0
Long-term investments			0
Other assets			(3)
Total assets			14
Current liabilities:
Accounts payable			0
Employee compensation and benefits			0
Deferred revenue			(11)
Other accrued liabilities			0
Total current liabilities			(11)
Long-term debt			0
Retirement and post-retirement benefits			0
Other long-term liabilities			2
Total liabilities			(9)
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding			0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018, issued			0
Additional paid-in-capital			0
Retained earnings (accumulated deficit)			23
Accumulated other comprehensive loss			0
Total stockholder's equity			23
Non-controlling interest			0
Total equity			23
Total liabilities and equity			14
Impact of Adopting New Tax Effects in AOCI Guidance
Current assets:
Cash and cash equivalents			0
Accounts receivable, net			0
Inventory			0
Other current assets			0
Total current assets			0
Property, plant and equipment, net			0
Goodwill			0
Other intangible assets, net			0
Long-term investments			0
Other assets			0
Total assets			0
Current liabilities:
Accounts payable			0
Employee compensation and benefits			0
Deferred revenue			0
Other accrued liabilities			0
Total current liabilities			0
Long-term debt			0
Retirement and post-retirement benefits			0
Other long-term liabilities			0
Total liabilities			0
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding			0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018, issued			0
Additional paid-in-capital			0
Retained earnings (accumulated deficit)			7
Accumulated other comprehensive loss			(7)
Total stockholder's equity			0
Non-controlling interest			0
Total equity			0
Total liabilities and equity			0
Impact of Adopting New Intra-Entity Tax Guidance
Current assets:
Cash and cash equivalents			0
Accounts receivable, net			0
Inventory			0
Other current assets			0
Total current assets			0
Property, plant and equipment, net			0
Goodwill			0
Other intangible assets, net			0
Long-term investments			0
Other assets			(2)
Total assets			(2)
Current liabilities:
Accounts payable			0
Employee compensation and benefits			0
Deferred revenue			0
Other accrued liabilities			0
Total current liabilities			0
Long-term debt			0
Retirement and post-retirement benefits			0
Other long-term liabilities			0
Total liabilities			0
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding			0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018, issued			0
Additional paid-in-capital			0
Retained earnings (accumulated deficit)			(2)
Accumulated other comprehensive loss			0
Total stockholder's equity			(2)
Non-controlling interest			0
Total equity			(2)
Total liabilities and equity			(2)
Impact of Adopting New Investments Valuation Guidance
Current assets:
Cash and cash equivalents			0
Accounts receivable, net			0
Inventory			0
Other current assets			0
Total current assets			0
Property, plant and equipment, net			0
Goodwill			0
Other intangible assets, net			0
Long-term investments			7
Other assets			(2)
Total assets			5
Current liabilities:
Accounts payable			0
Employee compensation and benefits			0
Deferred revenue			0
Other accrued liabilities			0
Total current liabilities			0
Long-term debt			0
Retirement and post-retirement benefits			0
Other long-term liabilities			0
Total liabilities			0
Stockholders' equity:
Preferred stock; $0.01 par value; 125 million shares authorized; none issued and outstanding			0
Common stock; $0.01 par value; 2 billion shares authorized; 318 million shares at October 31, 2018, issued			0
Additional paid-in-capital			0
Retained earnings (accumulated deficit)			5
Accumulated other comprehensive loss			0
Total stockholder's equity			5
Non-controlling interest			0
Total equity			5
Total liabilities and equity			$ 5

NEW ACCOUNTING PRONOUNCEMENTS_3

NEW ACCOUNTING PRONOUNCEMENTS- Textuals (Details) - USD ($) $ in Millions	Nov. 01, 2018	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Oct. 31, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%
Retained earnings (accumulated deficit)	$ (303)	$ 178		$ 178		$ (336)
Long-term Investments	75	96		96		$ 68
Impact of adoption of new guidance	(7)			(7)
Impact of Adopting New Revenue Guidance
Retained earnings (accumulated deficit)	23
Long-term Investments	0
Impact of Adopting New Tax Effects in AOCI Guidance
Retained earnings (accumulated deficit)	7
Long-term Investments	0
Impact of Adopting New Intra-Entity Tax Guidance
Retained earnings (accumulated deficit)	(2)
Long-term Investments	0
Impact of Adopting New Investments Valuation Guidance
Retained earnings (accumulated deficit)	5
Long-term Investments	$ 7
Impact of Adopting New Retirement Benefits Guidance
Impact of adoption of new guidance		$ 3	$ 5	$ 5	$ 15

NEW ACCOUNTING PRONOUNCEMENTS R

NEW ACCOUNTING PRONOUNCEMENTS Restricted Cash (Details) - USD ($) $ in Millions	Apr. 30, 2019	Nov. 01, 2018	Oct. 31, 2018	Apr. 30, 2018	Oct. 31, 2017
Statement of Financial Position [Abstract]
Cash and cash equivalents	$ 2,155	$ 2,247	$ 2,247
Restricted Cash, Noncurrent	6		7
Cash, cash equivalents and restricted cash	$ 2,161		$ 2,254	$ 3,018	$ 2,686

REVENUE- Revenue by Region (Det

REVENUE- Revenue by Region (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Net revenue	$ 1,238	$ 1,206	$ 2,522	$ 2,417
Life Sciences and Applied Markets
Net revenue	529	537	1,136	1,133
Agilent CrossLab
Net revenue	455	426	897	834
Diagnostics and Genomics
Net revenue	254	$ 243	489	$ 450
Americas
Net revenue	433		866
Americas | Life Sciences and Applied Markets
Net revenue	145		313
Americas | Agilent CrossLab
Net revenue	168		324
Americas | Diagnostics and Genomics
Net revenue	120		229
Europe
Net revenue	354		737
Europe | Life Sciences and Applied Markets
Net revenue	125		289
Europe | Agilent CrossLab
Net revenue	132		260
Europe | Diagnostics and Genomics
Net revenue	97		188
Asia Pacific
Net revenue	451		919
Asia Pacific | Life Sciences and Applied Markets
Net revenue	259		534
Asia Pacific | Agilent CrossLab
Net revenue	155		313
Asia Pacific | Diagnostics and Genomics
Net revenue	$ 37		$ 72

Revenue - Revenue by end Market

Revenue - Revenue by end Markets and by type (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Net revenue	$ 1,238	$ 1,206	$ 2,522	$ 2,417
Instrumentation
Net revenue	491		1,058
Non-Instrumentation and Other
Net revenue	747		1,464
Pharmaceutical and Biotechnology Market
Net revenue	371		762
Chemical and Energy Market
Net revenue	300		608
Diagnostics and Clinical Market
Net revenue	193		380
Food Market
Net revenue	114		243
Academia and Government Market
Net revenue	114		230
Environmental and Forensics Market
Net revenue	$ 146		$ 299

REVENUE - Contract Balances (De

REVENUE - Contract Balances (Details) - USD ($) $ in Millions	Nov. 01, 2018	Apr. 30, 2019	Oct. 31, 2018
Contract Assets
Contract Assets (Unbilled Accounts Receivable)	$ 57	$ 86
Transaction Price Allocated to Remaining Performance Obligation
Remaining Performance Obligation, Amount		174
Majority of Remaining Performance Obligation Expected Timing of Satisfaction, Period			12 months
Contract Liabilities
Contract liability ending balance as of October 31, 2018	367
Net revenue deferred in the period		224
Revenue recognized that was included in the contract liability balance at the beginning of the period		(191)
Change in deferrals from customer cash advances, net of revenue recognized		2
Contract liabilities acquired in business combinations		2
Currency Translation Adjustment		1
Contract liability ending balance as of January 31, 2019		394
Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Contract Assets
Contract Assets (Unbilled Accounts Receivable)		$ 29
Contract Liabilities
Impact of adoption of new guidance on contract liabilities (deferred revenue)	$ (11)

SHARE-BASED COMPENSATION Alloca

SHARE-BASED COMPENSATION Allocated Share-based compensation expense (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 16	$ 12	$ 40	$ 43
Cost of Products and Services
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	4	3	9	10
Research and Development Expense
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	2	1	4	4
Selling, General and Administrative Expenses
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 10	$ 8	$ 27	$ 29

SHARE-BASED COMPENSATION Fair V

SHARE-BASED COMPENSATION Fair Value Assumptions (Details)	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award
ESPP plan purchase price (in hundredths)	85.00%	85.00%	85.00%	85.00%
LTPP
Share-based Compensation Arrangement by Share-based Payment Award
Volatility of Agilent shares	22.00%	21.00%	22.00%	21.00%
Volatility of selected peer-company shares - Minimum	15.00%	14.00%	15.00%	14.00%
Volatility of selected peer-company shares - Maximum	66.00%	66.00%	66.00%	66.00%
Price-wise correlation with selected peers (in hundredths)	30.00%	32.00%	30.00%	32.00%
LTPP & RSU
Share-based Compensation Arrangement by Share-based Payment Award
Discount for postvesting restrictions	5.00%	4.80%	5.00%	4.80%

SHARE-BASED COMPENSATION Capita

SHARE-BASED COMPENSATION Capitalized (Details) - USD ($) $ in Millions	6 Months Ended	12 Months Ended
	Apr. 30, 2019	Oct. 31, 2018
Inventory
Share-based Compensation Arrangement by Share-based Payment Award
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost	$ 0	$ 0

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Income Tax Disclosure
Provision (benefit) for income taxes	$ 36	$ 22	$ (220)	$ 575
Effective income tax rate	16.50%	9.70%	(47.20%)	125.00%
Discrete tax expense (benefit)			$ (299)
Excess tax benefit from stock based compensation	$ (3)	$ (7)	$ (7)	$ (18)
U.S. Tax Cuts and Jobs Act of 2017
Income Tax Disclosure
Discrete tax expense related to enactment of the Tax Act				$ 533

NET INCOME PER SHARE (Details)

NET INCOME PER SHARE (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Numerator:
Net income (loss)	$ 182	$ 205	$ 686	$ (115)
Denominators:
Basic weighted-average shares (in shares)	317,000,000	322,000,000	318,000,000	323,000,000
Potential common shares - stock options and other employee stock plans (in shares)	4,000,000	4,000,000	4,000,000	0
Diluted weighted average shares (in shares)	321,000,000	326,000,000	322,000,000	323,000,000
Antidilutive securities excluded from computation of Earnings Per Share, amount (in shares)	0	96,800	0	6,600,000

INVENTORY (Details)

INVENTORY (Details) - USD ($) $ in Millions	Apr. 30, 2019	Nov. 01, 2018	Oct. 31, 2018
Inventory, Net [Abstract]
Finished goods	$ 401		$ 386
Purchased parts and fabricated assemblies	256		252
Inventory	$ 657	$ 628	$ 638

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill Roll forward (Details) $ in Millions	6 Months Ended
	Apr. 30, 2019USD ($)
Goodwill Roll Forward
Goodwill beginning balance	$ 2,973
Foreign currency translation impact	(3)
Goodwill arising from acquisitions	142
Goodwill ending balance	3,112
Life Sciences and Applied Markets
Goodwill Roll Forward
Goodwill beginning balance	803
Foreign currency translation impact	0
Goodwill arising from acquisitions	153
Goodwill ending balance	956
Diagnostics and Genomics
Goodwill Roll Forward
Goodwill beginning balance	1,607
Foreign currency translation impact	(2)
Measurement period adjustment to goodwill	(11)
Goodwill ending balance	1,594
Agilent CrossLab
Goodwill Roll Forward
Goodwill beginning balance	563
Foreign currency translation impact	(1)
Goodwill arising from acquisitions	0
Goodwill ending balance	$ 562

GOODWILL AND OTHER INTANGIBLE_4

GOODWILL AND OTHER INTANGIBLE ASSETS Disclosures and Components of Purchased Other Intangibles (Details) - USD ($) $ in Millions	Apr. 30, 2019	Nov. 01, 2018	Oct. 31, 2018
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	$ 1,445		$ 1,344
Accumulated Amortization	907		853
Net Book Value	538	$ 491	491
Purchased Technology
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1,026		947
Accumulated Amortization	720		683
Net Book Value	306		264
Trademark/Tradenames
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	153		151
Accumulated Amortization	95		88
Net Book Value	58		63
Customer Relationships
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	127		107
Accumulated Amortization	71		63
Net Book Value	56		44
Third-Party Technology and Licenses
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	28		28
Accumulated Amortization	21		19
Net Book Value	7		9
Total amortizable intangible assets
Finite-Lived Intangible Assets, Net
Gross Carrying Amount	1,334		1,233
Accumulated Amortization	907		853
Net Book Value	427		380
In-Process R&D
Indefinite-Lived Intangible Assets (Excluding Goodwill)
In-Process R&D	$ 111		$ 111

GOODWILL AND OTHER INTANGIBLE_5

GOODWILL AND OTHER INTANGIBLE ASSETS Textuals (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Finite-Lived Intangible Assets
Additions to goodwill			$ 142
Addition to other intangible assets			102
Impairment of IPR&D	$ 0	$ 0	0	$ 0
Goodwill impairment	0	0	0	0
Amortization of intangible assets during the period	26	$ 26	55	$ 52
Life Sciences and Applied Markets
Finite-Lived Intangible Assets
Additions to goodwill			153
Diagnostics and Genomics
Finite-Lived Intangible Assets
Measurement period adjustment to goodwill			$ (11)
ACEA Biosciences, Inc.
Acquisition
Purchase Price	$ 250

GOODWILL AND OTHER INTANGIBLE_6

GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS - Estimated Future Amortization (Details) $ in Millions	Apr. 30, 2019USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2019	$ 53
2020	94
2021	81
2022	65
2023	55
2024	46
Thereafter	$ 33

FAIR VALUE MEASUREMENTS, Fair v

FAIR VALUE MEASUREMENTS, Fair value of assets and liabilities measured on a recurring basis (Details) - Fair Value, Measurements, Recurring - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Assets Short - term
Cash equivalents (money market funds)	$ 1,229	$ 1,355
Derivative instruments (foreign exchange contracts)	6	16
Assets, Long-term
Trading securities	31	30
Other investments	24
Total assets measured at fair value	1,290	1,401
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	2	5
Liabilities Long-term
Deferred compensation liability	31	30
Total liabilities measured at fair value	33	35
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets Short - term
Cash equivalents (money market funds)	1,229	1,355
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term
Trading securities	31	30
Other investments	0
Total assets measured at fair value	1,260	1,385
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	0	0
Liabilities Long-term
Deferred compensation liability	0	0
Total liabilities measured at fair value	0	0
Significant Other Observable Inputs (Level 2)
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	6	16
Assets, Long-term
Trading securities	0	0
Other investments	24
Total assets measured at fair value	30	16
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	2	5
Liabilities Long-term
Deferred compensation liability	31	30
Total liabilities measured at fair value	33	35
Significant Unobservable Inputs (Level 3)
Assets Short - term
Cash equivalents (money market funds)	0	0
Derivative instruments (foreign exchange contracts)	0	0
Assets, Long-term
Trading securities	0	0
Other investments	0
Total assets measured at fair value	0	0
Liabilities, Short-term
Derivative instruments (foreign exchange contracts)	0	0
Liabilities Long-term
Deferred compensation liability	0	0
Total liabilities measured at fair value	$ 0	$ 0

FAIR VALUE MEASUREMENTS, Fair_2

FAIR VALUE MEASUREMENTS, Fair value measures and impairments (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Oct. 31, 2018
Long-Lived Assets
Impairment of Long-Lived Assets Held-for-use	$ 0	$ 0	$ 0	$ 0
Impairment of non-marketable securities	0		0
Impairment of long-lived assets held for sale	0	0	0	0
Non-marketable equity securities carrying amount	42		42		$ 23
Investments
Impairment of Investments	$ 0	$ 0	$ 0	$ 0

DERIVATIVES- Terminated Interes

DERIVATIVES- Terminated Interest Rate Swaps (Details) $ in Millions	Sep. 15, 2016USD ($)	Apr. 30, 2019USD ($)	Oct. 31, 2018USD ($)	Feb. 01, 2016USD ($)contracts	Jul. 01, 2012USD ($)	Aug. 09, 2011USD ($)contracts
Derivative Instruments and Hedging Activities Disclosure
Aggregate fair value of all derivative instruments with credit-risk-related contingent features that were in a net liability position		$ 1
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		5	$ 7
Senior Notes 2020
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		5	7
Senior Notes 2020 | Interest Rate Swap [Member] | Derivatives Designated as Hedging Instrument | Fair Value Hedging
Terminated Derivative Contracts
Number of interest rate swap contracts terminated | contracts						5
Notional amount of contract						$ 500
Remaining deferred gain (loss) to be amortized on derivative		5
Senior Notes 2022
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		0	0
Senior Notes 2022 | Treasury Lock [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Terminated Derivative Contracts
Notional amount of contract					$ 400
Remaining gain (loss) to be amortized on derivative		1
Senior Notes 2026
Terminated Derivative Contracts
Remaining deferred gain (loss) to be amortized on derivative		0	$ 0
Senior Notes 2026 | Interest Rate Swap [Member] | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Terminated Derivative Contracts
Number of interest rate swap contracts terminated | contracts				3
Notional amount of contract				$ 300
Interest rate swap payments	$ 10
Remaining gain (loss) to be amortized on derivative		$ 7

DERIVATIVES- Foreign Exchange F

DERIVATIVES- Foreign Exchange Forward Contracts (Details) $ in Millions	Apr. 30, 2019USD ($)contracts
Foreign Exchange Forward | Derivatives Designated as Hedging Instrument | Cash Flow Hedging
Derivative
Number of foreign exchange forward contracts (in units) | contracts	276
Foreign Exchange Forward | Derivatives Not Designated as Hedging Instruments
Derivative
Number of foreign exchange forward contracts (in units) | contracts	145
Sell | Forward Contracts USD | Cash Flow Hedging
Derivative
Total notional amount	$ 325
Sell | Forward Contracts USD | Cash Flow Hedging | Euro
Derivative
Total notional amount	57
Sell | Forward Contracts USD | Cash Flow Hedging | British Pound
Derivative
Total notional amount	56
Sell | Forward Contracts USD | Cash Flow Hedging | Canadian Dollar
Derivative
Total notional amount	30
Sell | Forward Contracts USD | Cash Flow Hedging | Japanese Yen
Derivative
Total notional amount	97
Sell | Forward Contracts USD | Cash Flow Hedging | Korean Won
Derivative
Total notional amount	50
Sell | Forward Contracts USD | Cash Flow Hedging | Chinese Yuan Renminbi
Derivative
Total notional amount	57
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments
Derivative
Total notional amount	49
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Canadian Dollar
Derivative
Total notional amount	4
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Malaysian Ringgit
Derivative
Total notional amount	2
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Danish Krone
Derivative
Total notional amount	4
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Korean Won
Derivative
Total notional amount	31
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Singapore Dollar
Derivative
Total notional amount	5
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Swiss Franc
Derivative
Total notional amount	7
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Chinese Yuan Renminbi
Derivative
Total notional amount	33
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Polish Zloty
Derivative
Total notional amount	3
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Swedish Krona
Derivative
Total notional amount	9
Sell | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Other
Derivative
Total notional amount	9
Buy | Forward Contracts USD | Cash Flow Hedging | Australian Dollar
Derivative
Total notional amount	5
Buy | Forward Contracts USD | Cash Flow Hedging | Singapore Dollar
Derivative
Total notional amount	17
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Euro
Derivative
Total notional amount	33
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | British Pound
Derivative
Total notional amount	7
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Australian Dollar
Derivative
Total notional amount	4
Buy | Forward Contracts USD | Derivatives Not Designated as Hedging Instruments | Japanese Yen
Derivative
Total notional amount	$ 14

DERIVATIVES, Fair value of deri

DERIVATIVES, Fair value of derivative instruments and Consolidated Balance Sheet location (Details) - USD ($) $ in Millions	Apr. 30, 2019	Oct. 31, 2018
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	$ 6	$ 16
Derivatives liabilities fair value	2	5
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	4	11
Derivatives Designated as Hedging Instruments | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	1	1
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts [Member] | Other Current Assets
Derivative Fair Value by Balance Sheet Location
Derivatives asset fair value	2	5
Derivatives Not Designated as Hedging Instruments | Foreign Exchange Contracts [Member] | Other Accrued Liabilities
Derivative Fair Value by Balance Sheet Location
Derivatives liabilities fair value	$ 1	$ 4

DERIVATIVES, Effect of derivati

DERIVATIVES, Effect of derivative instruments on Consolidated Statement of Operations (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Derivative
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales	$ 0	$ (5)	$ 5	$ (5)
Cash Flow Hedging | Cost of Sales
Derivative
Cash flow hedge net gain to be reclassified within next Twelve Months	5
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Accumulated Other Comprehensive Income (Loss)
Derivative
Gain (loss) recognized in accumulated other comprehensive income (loss)	4	5	(2)	(5)
Derivatives Designated as Hedging Instrument | Cash Flow Hedging | Foreign Exchange Contracts [Member] | Cost of Sales
Derivative
Gain (loss) reclassified from accumulated other comprehensive income (loss) into cost of sales	0	(5)	5	(5)
Gain on time value of forward contracts recorded in cost of sales	1	0	2	0
Derivatives Not Designated as Hedging Instruments | Other income (expense)
Derivative
Gain (loss) recognized in other income (expense)	$ 1	$ (5)	$ (2)	$ 1

RETIREMENT PLANS AND POST RET_3

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS- Components of net periodic costs (Details) - USD ($) $ in Millions	3 Months Ended				6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Jan. 31, 2018	Jan. 31, 2017	Apr. 30, 2019	Apr. 30, 2018
Pension Plan [Member] | Domestic Plan [Member]
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	$ 0	$ 0			$ 0	$ 0
Interest cost on benefit obligation	5	4			10	8
Expected return on plan assets	(7)	(7)			(14)	(14)
Amortization:
Actuarial losses	0	0			0	0
Prior service credits	0	0			0	0
Total net plan costs	(2)	(3)			(4)	(6)
Pension Plan [Member] | Foreign Plan [Member]
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	4	4			10	10
Interest cost on benefit obligation	3	3			6	6
Expected return on plan assets	(11)	(12)			(22)	(23)
Amortization:
Actuarial losses	9	8			18	15
Prior service credits	0	0			0	0
Total net plan costs	5	3			12	8
Curtailments and Settlements
Settlement gain			$ 5	$ 32	0	5
Other Postretirement Benefits Plan [Member] | Domestic Plan [Member]
Defined Benefit Plan, Net Periodic Benefit Cost
Service cost - benefits earned during the period	0	0			0	0
Interest cost on benefit obligation	1	1			1	2
Expected return on plan assets	(1)	(2)			(2)	(4)
Amortization:
Actuarial losses	1	2			2	4
Prior service credits	(2)	(2)			(4)	(4)
Total net plan costs	$ (1)	$ (1)			$ (3)	$ (2)

RETIREMENT PLANS AND POST RET_4

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS (Details) (Textual) - Pension Plan [Member] - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Domestic Plan [Member]
Defined Benefit Plans Contributions
Contributions to defined benefit plans	$ 0	$ 0	$ 0	$ 0
Estimated future employer contributions in remainder of current fiscal year	0		0
Foreign Plan [Member]
Defined Benefit Plans Contributions
Contributions to defined benefit plans	5	$ 5	11	$ 11
Estimated future employer contributions in remainder of current fiscal year	$ 15		$ 15

RETIREMENT PLANS AND POST RET_5

RETIREMENT PLANS AND POST RETIREMENT PENSION PLANS - JWPIL (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Apr. 30, 2019	Apr. 30, 2018
Pension Plan [Member] | Foreign Plan [Member]
Defined Benefit Plan Disclosure
Settlement gain	$ 5	$ 32	$ 0	$ 5

WARRANTIES AND CONTINGENCIES (D

WARRANTIES AND CONTINGENCIES (Details) - USD ($) $ in Millions	6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018
Movement in Standard Product Warranty Accrual
Beginning balance at beginning of period	$ 35	$ 34
Accruals for warranties including change in estimate	27	25
Settlements made during the period	(30)	(26)
Ending balance at end of period	32	33
Standard Product Warranty Disclosure
Accruals for warranties due within one year	$ 32	$ 33

SHORT-TERM DEBT Credit Facility

SHORT-TERM DEBT Credit Facility (Details) - USD ($) $ in Millions	Mar. 13, 2019	Apr. 30, 2019
Line of Credit Facility
Initiation date of credit facility	Mar. 13, 2019
Expiration date of credit facility	Mar. 13, 2024
Credit faciity terms (in years)	five
New maximum borrowing capacity of credit facility		$ 1,000
Amount outstanding on credit facility		$ 0

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($) $ in Millions	Apr. 30, 2019	Nov. 01, 2018	Oct. 31, 2018
Debt Instrument
Long-term debt	$ 1,793		$ 1,792
Interest rate swap	5		7
Long-term Debt, Excluding Current Maturities	1,798	$ 1,799	1,799
Senior Notes 2020
Debt Instrument
Long-term debt	499		499
Interest rate swap	5		7
Long-term Debt, Excluding Current Maturities	504		506
Senior Notes 2022
Debt Instrument
Long-term debt	399		399
Interest rate swap	0		0
Long-term Debt, Excluding Current Maturities	399		399
Senior Notes 2023
Debt Instrument
Long-term debt	597		597
Interest rate swap	0		0
Long-term Debt, Excluding Current Maturities	597		597
Senior Notes 2026
Debt Instrument
Long-term debt	298		297
Interest rate swap	0		0
Long-term Debt, Excluding Current Maturities	$ 298		$ 297

STOCKHOLDERS' EQUITY - Stock Re

STOCKHOLDERS' EQUITY - Stock Repurchase Program (Details) - USD ($) $ in Millions	May 01, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018	Nov. 19, 2018	Nov. 01, 2018	May 28, 2015
Share repurchase program
Stock repurchased during the period - value		$ 50	$ 46	$ 125	$ 93
Aggregate cost of shares repurchased				125	93
Treasury Stock Retired
Treasury Stock, Retired, Cost Method, Amount		$ 0	$ 0	$ 0	$ 0
2019 Repurchase Program [Member]
Share repurchase program
Share repurchase program authorized amount						$ 1,750
Stock repurchased (in shares)		638,000		1,766,000
Stock repurchased during the period - value		$ 50		$ 125
Remaining authorized repurchase amount under share repurchase program		$ 1,625		$ 1,625
Treasury Stock Retired
Number of treasury shares retired (in shares)		629,000		1,757,000
Treasury Stock, Retired, Cost Method, Amount		$ 49		$ 124
2015 Repurchase Program
Share repurchase program
Share repurchase program authorized amount								$ 1,140
Stock repurchased (in shares)			674,000		1,300,000
Stock repurchased during the period - value			$ 46		$ 93
Remaining authorized repurchase amount under share repurchase program							$ 188
Treasury Stock Retired
Number of treasury shares retired (in shares)			711,000		1,300,000
Treasury Stock, Retired, Cost Method, Amount			$ 49		$ 93
Subsequent Event [Member] | 2019 Repurchase Program [Member]
Treasury Stock Retired
Number of treasury shares retired (in shares)	9,000

STOCKHOLDER"S EQUITY - Dividend

STOCKHOLDER"S EQUITY - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	May 22, 2019	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Dividends Paid
Aggregate amount of cash dividends paid		$ 52	$ 48	$ 104	$ 96
Common Stock, Dividends, Per Share, Declared		$ 0.164	$ 0.149	$ 0.328	$ 0.298
Dividends, Common Stock, Cash		$ 52	$ 48	$ 104	$ 96
Subsequent Event [Member]
Dividends Paid
Dividends Payable, Date Declared	May 22, 2019
Common Stock, Dividends, Per Share, Declared	$ 0.164
Dividends, Common Stock, Cash	$ 53
Dividends Payable, Date to be Paid	Jul. 24, 2019
Dividends Payable, Date of Record	Jul. 2, 2019

STOCKHOLDER'S EQUITY - Accumula

STOCKHOLDER'S EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	Nov. 01, 2018	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Beginning Balance	$ (408)	$ (381)		$ (408)
Impact of adoption of new guidance on tax effects in AOCI	(7)			(7)
Other comprehensive income (loss) before reclassifications		(23)		0
Amounts reclassified out of accumulated other comprehensive income (loss)		8		11
Tax expense (benefit)		(2)		(6)
Other comprehensive income (loss)		(17)	$ (41)	17	$ 36
Ending Balance	(415)	(398)		(398)
Foreign Currency Translation
Beginning Balance	(214)	(176)		(214)
Impact of adoption of new guidance on tax effects in AOCI	0			0
Other comprehensive income (loss) before reclassifications		(25)		4
Amounts reclassified out of accumulated other comprehensive income (loss)		0		0
Tax expense (benefit)		0		9
Other comprehensive income (loss)		(25)		13
Ending Balance	(214)	(201)		(201)
Prior Service Credits
Beginning Balance	134	135		134
Impact of adoption of new guidance on tax effects in AOCI	3			3
Other comprehensive income (loss) before reclassifications		0		0
Amounts reclassified out of accumulated other comprehensive income (loss)		(2)		(4)
Tax expense (benefit)		1		1
Other comprehensive income (loss)		(1)		(3)
Ending Balance	137	134		134
Actuarial Losses
Beginning Balance	(335)	(338)		(335)
Impact of adoption of new guidance on tax effects in AOCI	(9)			(9)
Other comprehensive income (loss) before reclassifications		(2)		(2)
Amounts reclassified out of accumulated other comprehensive income (loss)		10		20
Tax expense (benefit)		(2)		(6)
Other comprehensive income (loss)		6		12
Ending Balance	(344)	(332)		(332)
Unrealized Gains (Losses) on Derivatives
Beginning Balance	7	(2)		7
Impact of adoption of new guidance on tax effects in AOCI	(1)			(1)
Other comprehensive income (loss) before reclassifications		4		(2)
Amounts reclassified out of accumulated other comprehensive income (loss)		0		(5)
Tax expense (benefit)		(1)		2
Other comprehensive income (loss)		3		(5)
Ending Balance	$ 6	$ 1		$ 1

STOCKHOLDERS' EQUITY - Reclassi

STOCKHOLDERS' EQUITY - Reclassifications out of accumulated comprehensive income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives
Unrealized gain (loss) on derivatives	$ 0	$ (5)	$ 5	$ (5)
Unrealized gains and (losses) on derivatives reclassified to cost of products, before tax	0	(5)	5	(5)
Reclassification of (gains) and losses into earnings related to derivative instruments, tax	0	2	(1)	2
Unrealized gains and (losses) on derivatives reclassified to cost of products, net of tax	0	(3)	4	(3)
Actuarial net loss	(10)	(10)	(20)	(19)
Prior service benefit	2	2	4	4
Actuarial net loss and prior service benefit reclassified, before tax	(8)	(8)	(16)	(15)
Tax on actuarial net loss and prior service benefit reclassified	1	3	5	4
Actuarial net loss and prior service benefit reclassified, net of tax	(7)	(5)	(11)	(11)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	$ (7)	$ (8)	$ (7)	$ (14)

SEGMENT INFORMATION - Profitabi

SEGMENT INFORMATION - Profitability (Details) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019USD ($)	Apr. 30, 2018USD ($)	Apr. 30, 2019USD ($)	Apr. 30, 2018USD ($)
Segment Reporting Information
Number of operating segments	3
Segment Reporting Information
Net revenue	$ 1,238	$ 1,206	$ 2,522	$ 2,417
Income from operations	216	210	466	439
Life Sciences and Applied Markets
Segment Reporting Information
Net revenue	529	537	1,136	1,133
Income from operations	107	113	266	267
Diagnostics and Genomics
Segment Reporting Information
Net revenue	254	243	489	450
Income from operations	49	48	82	72
Agilent CrossLab
Segment Reporting Information
Net revenue	455	426	897	834
Income from operations	115	96	220	183
Segment Total
Segment Reporting Information
Net revenue	1,238	1,206	2,522	2,417
Income from operations	$ 271	$ 257	$ 568	$ 522

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Reportable Results (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Reconciliation of Operating Profit from Segments to Consolidated
Total reportable segment's income from operations	$ 271	$ 257	$ 568	$ 522
Transformational initiatives	(9)	(5)	(14)	(9)
Amortization of intangible assets related to business combinations	(26)	(25)	(54)	(50)
Acquisition and integration costs	(10)	(4)	(20)	(7)
Business exit and divestiture costs	0	(8)	0	(8)
NASD site costs	(4)	(2)	(6)	(4)
Special compliance costs	(1)	(1)	(1)	(2)
Other	(5)	(2)	(7)	(3)
Interest income	10	10	20	19
Interest expense	(17)	(19)	(35)	(39)
Other income (expense), net	9	26	15	41
Income before taxes, as reported	$ 218	$ 227	$ 466	$ 460

SEGMENT INFORMATION - Segment A

SEGMENT INFORMATION - Segment Assets (Details) - USD ($) $ in Millions	Apr. 30, 2019	Nov. 01, 2018	Oct. 31, 2018
Segment Reporting Information
Assets	$ 9,022	$ 8,558	$ 8,541
Life Sciences and Applied Markets
Segment Reporting Information
Assets	2,023		1,744
Diagnostics and Genomics
Segment Reporting Information
Assets	2,617		2,679
Agilent CrossLab
Segment Reporting Information
Assets	1,307		1,267
Segment Total
Segment Reporting Information
Assets	$ 5,947		$ 5,690